0001683168-20-001561.txt : 20200514 0001683168-20-001561.hdr.sgml : 20200514 20200514160137 ACCESSION NUMBER: 0001683168-20-001561 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 49 CONFORMED PERIOD OF REPORT: 20200331 FILED AS OF DATE: 20200514 DATE AS OF CHANGE: 20200514 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PRECISION OPTICS CORPORATION, INC. CENTRAL INDEX KEY: 0000867840 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 042795294 STATE OF INCORPORATION: MA FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-10647 FILM NUMBER: 20877625 BUSINESS ADDRESS: STREET 1: 22 EAST BROADWAY CITY: GARDNER STATE: MA ZIP: 01440 BUSINESS PHONE: 978-630-1800 MAIL ADDRESS: STREET 1: 22 EAST BROADWAY CITY: GARDNER STATE: MA ZIP: 01440 FORMER COMPANY: FORMER CONFORMED NAME: PRECISION OPTICS Corp INC DATE OF NAME CHANGE: 20111027 FORMER COMPANY: FORMER CONFORMED NAME: PRECISION OPTICS CORPORATION INC DATE OF NAME CHANGE: 19930328 FORMER COMPANY: FORMER CONFORMED NAME: PRECISION OPTICS CORP INC DATE OF NAME CHANGE: 19600201 10-Q 1 precision_10q-033120.htm FORM 10-Q

 

Table of Contents

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2020

 

or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                      to                     

 

Commission File Number: 001-10647

 

PRECISION OPTICS CORPORATION, INC.

(Exact name of registrant as specified in its charter)

 

Massachusetts 04-2795294
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)

 

22 East Broadway, Gardner, Massachusetts 01440-3338

(Address of principal executive offices) (Zip Code)

 

(978) 630-1800

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act: None.

 

Securities registered pursuant to Section 12(g) of the Act:

 

Title of each class Trading symbol(s) Name of each exchange on which registered
Common Stock, $0.01 par value PEYE OTCQB

  

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer   Accelerated filer
Non-accelerated filer   Smaller reporting company
      Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

The number of shares outstanding of the issuer’s common stock, par value $0.01 per share, at May 14, 2020 was 13,191,789 shares.

 

 

 

 

 

PRECISION OPTICS CORPORATION, INC.

 

Table of Contents

 

  Page
PART I — FINANCIAL INFORMATION 3
Item 1. Financial Statements 3
Consolidated Balance Sheets at March 31, 2020 and June 30, 2019 3
Consolidated Statements of Operations for the Three and Nine Months Ended March 31, 2020 and 2019 4
Consolidated Statements of Stockholders’ Equity for the Three and Nine Months Ended March 31, 2020 and 2019 5
Consolidated Statements of Cash Flows for the Nine Months Ended March 31, 2020 and 2019 6
Notes to Consolidated Financial Statements 7
   
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 14
Item 3. Quantitative and Qualitative Disclosures About Market Risk 19
Item 4. Controls and Procedures 19
   
PART II — OTHER INFORMATION 21
Item 1. Legal Proceedings 21
Item 1A. Risk Factors 21
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 21
Item 3. Defaults Upon Senior Securities 22
Item 4. Mine Safety Disclosures (Not applicable.) 22
Item 5. Other Information 22
Item 6. Exhibits 23

 

 

 

 2 

 

 

PART I. FINANCIAL INFORMATION

  

Item 1. Financial Statements.

   

PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

 

 

   March 31,
2020
   June 30,
2019
 
ASSETS          
Current Assets:          
Cash and cash equivalents  $632,131   $2,288,426 
Accounts receivable (net of allowance for doubtful accounts of $247,701 and $246,953 at March 31, 2020 and June 30, 2019, respectively)   1,479,077    2,165,107 
Inventories   2,167,523    1,734,604 
Prepaid expenses   131,279    180,336 
Total current assets   4,410,010    6,368,473 
           
Fixed Assets:          
Machinery and equipment   2,905,516    2,748,715 
Leasehold improvements   724,680    668,446 
Furniture and fixtures   178,640    168,450 
    3,808,836    3,585,611 
Less—Accumulated depreciation and amortization   3,278,054    3,202,605 
Net Fixed Assets   530,782    383,006 
           
Operating lease right-to-use asset   132,000     
Patents, net   86,908    54,087 
Goodwill   687,664    687,664 
           
TOTAL ASSETS  $5,847,364   $7,493,230 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current Liabilities:          
Current portion of capital lease obligation  $70,436   $9,572 
Accounts payable   1,533,342    1,174,263 
Customer advances   310,525    450,192 
Accrued compensation and other   483,781    533,944 
Amount due for business acquisition       1,443,341 
Operating lease liability   56,196     
Total Current Liabilities   2,454,280    3,611,312 
           
Capital lease obligation, net of current portion   38,001    5,027 
Acquisition earn out liability   500,000    500,000 
Operating lease liability   75,804     
           
Stockholders’ Equity:          
Common stock, $0.01 par value: 50,000,000 shares authorized; issued and outstanding – 12,991,789 shares at March 31, 2020 and 12,071,139 shares at June 30, 2019   129,918    120,712 
Additional paid-in capital   49,389,419    48,893,172 
Accumulated deficit   (46,740,058)   (45,636,993)
Total stockholders’ equity   2,779,279    3,376,891 
           
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $5,847,364   $7,493,230 

 

 

The accompanying notes are an integral part of these consolidated interim financial statements.

 

 3 

 

 

PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE THREE AND NINE MONTHS ENDED

March 31, 2020 AND 2019

(UNAUDITED)

 

 

   Three Months
Ended March 31,
   Nine Months
Ended March 31,
 
   2020   2019   2020   2019 
Revenues  $2,374,584   $1,386,454   $7,686,330   $4,423,763 
                     
Cost of goods sold   1,557,565    930,518    4,977,255    3,149,598 
Gross profit   817,019    455,936    2,709,075    1,274,165 
                     
Research and development expenses, net   319,875    121,640    700,605    347,851 
Selling, general and administrative expenses   962,591    414,475    3,111,397    1,430,880 
Total operating expenses   1,282,466    536,115    3,812,002    1,778,731 
                     
Operating loss   (465,447)   (80,179)   (1,102,927)   (504,566)
                     
Interest income (expense)   (683)   (304)   (138)   (1,150)
                     
Net Loss  $(466,130)  $(80,483)  $(1,103,065)  $(505,716)
                     
Loss Per Share:                    
Basic and diluted  $(0.04)  $(0.01)  $(0.09)  $(0.04)
                     
Weighted Average Common Shares Outstanding:                    
Basic and diluted   12,982,494    12,020,328    12,898,004    11,294,902 

 

 

The accompanying notes are an integral part of these consolidated interim financial statements.

 

 4 

 

 

PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

FOR THE THREE AND NINE MONTHS ENDED

March 31, 2020 AND 2019

(UNAUDITED)

 

   Nine Month Period Ended March 31, 2020 
   Number of
Shares
   Common
Stock
   Additional
Paid-in
Capital
   Accumulated
Deficit
   Total
Stockholders’
Equity
 
                     
Balance, July 1, 2019   12,071,139   $120,712   $48,893,172   $(45,636,993)  $3,376,891 
Issuance of common stock in private placement   760,000    7,600    17,400        25,000 
Proceeds from exercise of stock options   12,500    125    8,550        8,675 
Issuance of common stock for services   25,000    250    44,750        45,000 
Stock-based compensation           76,505        76,505 
Net loss               (86,110)   (86,110)
Balance, September 30, 2019   12,868,639    128,687    49,040,377    (45,723,103)   3,445,961 
                          
Exercise of stock options net of 3,592 shares withheld   11,408    114    (114)        
Stock-based compensation           274,706        274,706 
Net loss               (550,825)   (550,825)
Balance, December 31, 2019   12,880,047    128,801    49,314,969    (46,273,928)   3,169,842 
                          
Issuance of common stock for services   100,000    1,000    (1,000)        
Exercise of stock options net of 8,258 shares withheld   11,742    117    (117)        
Stock-based compensation           75,567        75,567 
Net loss               (466,130)   (466,130)
Balance, March 31, 2020   12,991,789   $129,918   $49,389,419   $(46,740,058)  $2,779,279 

 

   Nine Month Period Ended March 31, 2019 
   Number of
Shares
   Common
Stock
   Additional
Paid-in
Capital
   Accumulated
Deficit
   Total
Stockholders’
Equity
 
                     
Balance, July 1, 2018   10,197,139   $101,972   $45,484,186   $(45,022,122)  $564,036 
Issuance of common stock for services   100,000    1,000    (1,000)        
Stock-based compensation           342,984        342,984 
Net loss               (299,285)   (299,285)
Balance, September 30, 2018   10,297,139    102,972    45,826,170    (45,321,407)   607,735 
                          
Private placement of common stock, net of issuance costs of $23,000   1,600,000    16,000    1,961,000        1,977,000 
Stock-based compensation           10,228        10,228 
Net loss               (125,948)   (125,948)
Balance, December 31, 2018   11,897,139    118,972    47,797,398    (45,447,355)   2,469,015 
                          
Issuance of common stock for services   100,000    1,000    (1,000)        
Exercise of stock options   41,000    410    28,965        29,375 
Adjust common stock issuance costs to actual           10,750        10,750 
Stock-based compensation           2,891        2,891 
Net loss               (80,483)   (80,483)
Balance, March 31, 2019   12,038,139   $120,382   $47,839,004   $(45,527,838)  $2,431,548 

 

 

The accompanying notes are an integral part of these consolidated interim financial statements.

 

 5 

 

 

PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE NINE MONTHS ENDED

March 31, 2020 AND 2019

(UNAUDITED)

 

 

   Nine Months
Ended March 31,
 
   2020   2019 
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net Loss  $(1,103,065)  $(505,716)
Adjustments to Reconcile Net Loss to Net Cash Used In Operating Activities -          
Depreciation and amortization   75,449    23,482 
Stock-based compensation expense   426,778    356,103 
Non-cash consulting expense   45,000     
Changes in Operating Assets and Liabilities -          
Accounts receivable, net   686,030    (29,905)
Inventories   (432,919)   14,222 
Prepaid expenses   49,057    (68,447)
Accounts payable   359,079    (59,721)
Customer advances   (139,667)   (598,914)
Accrued compensation and other   (50,163)   (85,236)
Net Cash Used In Operating Activities   (84,421)   (954,132)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Cash Paid for Business Acquisition   (1,443,341)    
Additional patent costs   (32,821)   (2,532)
Purchases of property and equipment   (110,012)   (111,766)
Net Cash Used In Investing Activities   (1,586,174)   (114,298)
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Payment of capital lease obligation   (19,375)   (6,666)
Gross proceeds from private placement of common stock   25,000    2,000,000 
Gross proceeds from exercise of stock options   8,675    29,375 
Private placement expense paid       (4,250)
Net Cash Provided From Financing Activities   14,300    2,018,459 
           
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS   (1,656,295)   950,029 
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD   2,288,426    402,738 
           
CASH AND CASH EQUIVALENTS, END OF PERIOD  $632,131   $1,352,767 
           
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:           
Cash paid for income taxes  $   $912 
           
SUPPLEMENTAL DISCLOSURE OF NON-CASH FINANCING AND INVESTING ACTIVITIES:          
Offering Costs Included in Accrued Liabilities  $23,000   $8,000 
Acquisition of Manufacturing Equipment Under Capital Lease  $113,213   $ 

 

 

The accompanying notes are an integral part of these consolidated interim financial statements.

 

 6 

 

 

PRECISION OPTICS CORPORATION, INC.

NOTES TO CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

 

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Principles of Consolidation and Operations

 

The accompanying consolidated financial statements include the accounts of Precision Optics Corporation, Inc. and its wholly owned subsidiaries (the “Company”). All significant intercompany accounts and transactions have been eliminated in consolidation.

 

These consolidated financial statements have been prepared by the Company, without audit, and reflect normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the results of the third quarter and nine months of the Company’s fiscal year 2020. These consolidated financial statements do not include all disclosures associated with annual consolidated financial statements and, accordingly, should be read in conjunction with footnotes contained in the Company’s consolidated financial statements for the year ended June 30, 2019, together with the Report of Independent Registered Public Accounting Firm filed under cover of the Company’s 2019 Annual Report on Form 10-K, filed with the Securities and Exchange Commission on September 26, 2019.

 

Use of Estimates

 

The preparation of these consolidated financial statements requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

 

Reclassification

 

Certain balance sheet items in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. This reclassification had no effect on the previously reported net loss.

 

Income (Loss) Per Share

 

Basic income (loss) per share is computed by dividing net income or net loss by the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share is computed by dividing net income or net loss by the weighted average number of shares of common stock outstanding during the period, plus the number of potentially dilutive securities outstanding during the period such as stock options and warrants. For the three and nine months ended March 31, 2020 and 2019, the effect of such securities was antidilutive and not included in the diluted calculation because of the net loss generated in these periods.

 

 

 

 7 

 

 

The following is the calculation of loss per share for the three and nine months ended March 31, 2020 and 2019:

 

   Three Months
Ended March 31,
   Nine Months
Ended March 31,
 
   2020   2019   2020   2019 
Net Loss - Basic and Diluted  $(466,130)  $(80,483)  $(1,103,065)  $(505,716)
                     
Basic and Dilutive Weighted Average Shares Outstanding   12,982,494    12,020,328    12,898,004    11,294,902 
                     
Loss Per Share - Basic and Diluted  $(0.04)  $(0.01)  $(0.09)  $(0.04)

 

The number of shares issuable upon the exercise of outstanding stock options and warrants that were excluded from the computation as their effect was antidilutive was approximately 2,072,800 and 1,462,000 for the three and nine months ended March 31, 2020 and 2019, respectively.

   

Income Taxes

 

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

 

In assessing the likelihood of utilization of existing deferred tax assets, management has considered historical results of operations and the current operating environment. Based on this evaluation, a full valuation reserve has been provided for the deferred tax assets.

 

Goodwill and Patents

 

Long-lived assets such as goodwill and patents are capitalized when acquired and reviewed for impairment whenever events or changes in circumstances indicate that the book value of the asset may not be recoverable. Impairment of the carrying value of long-lived assets such as goodwill and patents would be indicated if the best estimate of future undiscounted cash flows expected to be generated by the asset grouping is less than its carrying value. If an impairment is indicated, any loss is measured as the difference between estimated fair value and carrying value and is recognized in operating income or loss. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. No such impairments of goodwill or patents have been estimated by management as of March 31, 2020.

 

Accounting Pronouncements Recently Adopted

 

On July 1, 2019, the Company adopted ASU 2016-02, Topic 842 – Leases. Refer to Note 3 for further information.

 

 

 

 8 

 

 

2. INVENTORIES

 

Inventories are stated at the lower of cost (first-in, first-out) and net realizable value and consisted of the following:

 

   March 31,
2020
   June 30,
2019
 
Raw Materials  $651,939   $578,856 
Work-In-Progress   743,100    409,019 
Finished Goods   772,484    746,729 
Total Inventories  $2,167,523   $1,734,604 

 

3. LEASE OBLIGATIONS

 

The Company entered into a five-year capital lease obligation in January 2016 for the acquisition of manufacturing equipment totaling $51,252. In January 2020 the Company entered into a five-year capital lease and a twelve-month operating lease for $47,750 and $65,463 respectively for the acquisition of manufacturing equipment.

  

In February 2016, FASB issued ASU 2016-02, “Leases” (Topic 842). ASU 2016-02 requires the recognition of lease asset and lease liabilities by lessees for those leases currently classified as operating leases with terms greater than twelve months and make certain changes to the accounting for lease expenses. The Company adopted this standard effective July 1, 2019 and has reflected its impact upon the El Paso, Texas facility operating lease entered into on July 1, 2019 in connection with the Ross Optical acquisition. The facility lease is a three-year operating lease obligation with total remaining minimum lease payments of $139,791 at March 31, 2020. Total rent expense including base rent and common area expenses were $15,190 and $45,571 during the three and nine months ended March 31, 2020, respectively. Included in the accompanying balance sheet at March 31, 2020 is a right-of-use asset of $132,000 and current and long-term right-of-use operating lease liabilities of $56,196 and $75,804, respectively.

 

At March 31, 2020, future minimum lease payments under the capital lease and operating lease obligations are as follows:

 

Fiscal Year Ending June 30:   Capital Leases     Operating Lease  
2020   $ 21,748     $ 15,190  
2021     54,593       61,779  
2022     11,280       62,822  
2023     11,280        
2024     11,280        
2025     6,580        
Total Minimum Payments     116,761     $ 139,791  
Less: amount representing interest     8,324          
Present value of minimum lease payments     108,437          
Less: current portion     70,436          
    $ 38,001          

 

 

 

 9 

 

 

4. STOCK-BASED COMPENSATION

 

The following table summarizes stock-based compensation expense for the three and nine months ended March 31, 2020 and 2019:

 

   Three Months
Ended March 31,
   Nine Months
Ended March 31,
 
   2020   2019   2020   2019 
Cost of Goods Sold  $11,233   $   $33,699   $ 
Research and Development   21,346    2,411    46,714    7,233 
Selling, General and Administrative   42,988    480    346,365    348,870 
Stock Based Compensation Expense  $75,567   $2,891   $426,778   $356,103 

  

No compensation has been capitalized because such amounts would have been immaterial.

   

The following tables summarize stock option activity for the nine months ended March 31, 2020:

 

    Options Outstanding  
    Number of
Shares
    Weighted Average
Exercise Price
    Weighted Average
Contractual Life
 
Outstanding at June 30, 2019     1,819,500     $    0.87       7.05 years  
Granted     315,000                  
Exercised     (47,500 )                
Expired or Cancelled     (14,200 )                
Outstanding at March 31, 2020     2,072,800     $ 0.95       6.82 years  

 

Information related to the stock options outstanding as of March 31, 2020 is as follows:

 

Range of Exercise
Prices
    Number of
Shares
    Weighted-
Average
Remaining
Contractual Life
(years)
    Weighted-
Average
Exercise
Price
    Exercisable
Number of
Shares
    Exercisable
Weighted-
Average
Exercise
Price
 
$ 0.27       40,000       1.29     $ 0.27       40,000     $ 0.27  
$ 0.48       60,000       6.00     $ 0.48       60,000     $ 0.48  
$ 0.50       100,000       5.22     $ 0.50       100,000     $ 0.50  
$ 0.55       44,000       3.96     $ 0.55       44,000     $ 0.55  
$ 0.70       100,000       8.35     $ 0.70       100,000     $ 0.70  
$ 0.73       786,000       6.56     $ 0.73       786,000     $ 0.73  
$ 0.85       6,000       2.76     $ 0.85       6,000     $ 0.85  
$ 0.90       36,000       4.19     $ 0.90       36,000     $ 0.90  
$ 1.20       207,800       1.92     $ 1.20       207,800     $ 1.20  
$ 1.25       45,000       1.25     $ 1.25       -     $ -  
$ 1.30       478,000       9.20     $ 1.30       -     $ -  
$ 1.42       100,000       9.45     $ 1.42       -     $ -  
$ 1.50       70,000       9.96     $ 1.50       70,000     $ 1.50  
$ 0.27–$1.50       2,072,800       6.82     $ 0.95       1,449,800     $ 0.79  

 

 

 

 10 

 

 

The aggregate intrinsic value of the Company’s “in-the-money” outstanding and exercisable options as of the three and nine months ended March 31, 2020 was $941,830 and $887,280, respectively.

 

Common Stock Award

 

On August 2, 2018, the Company awarded its Chief Executive Officer 300,000 shares of common stock for services performed through June 30, 2018. The fair market value of the 300,000 shares on the award date equal to $210,000 has been recorded as general and administrative stock-based compensation expense in the quarter ended September 30, 2018. As of March 31, 2020, all 300,000 shares have been issued.

 

5. REVENUE RECOGNITION

 

On July 1, 2018, the Company adopted ASU 2014-09 Revenue from Contracts with Customers (ASC 606) using the modified retrospective method for contracts that were not completed as of July 1, 2018, whereby revenues are recognized as the performance obligations to deliver products or services are satisfied and are recorded based on the amount of consideration the Company expects to receive in exchange for satisfying the performance obligations. Most of the Company’s products and services are marketed to medical device companies almost exclusively in the United States. Products and services are primarily transferred to customers at a point in time based upon when services are performed or product is shipped.

 

Revenues represent the amount of consideration the Company expects to receive from customers in exchange for transferring products and services. Other selling costs to obtain and fulfill contracts are expensed as incurred due to the short-term nature of a majority of its revenues. The Company extends terms of payment to its customers based on commercially reasonable terms for the markets of its customers, while also considering their credit quality. Shipping and handling costs charged to customers are included in revenues.

 

The Company disaggregates revenues by product and service types as it believes it best depicts how the nature, amount, timing and uncertainty of revenues and cash flows are affected by economic factors. Revenues are comprised of the following for the three and nine months ended March 31, 2020 and 2019:

 

   Three Months
Ended March 31,
   Nine Months
Ended March 31,
 
   2020   2019   2020   2019 
Engineering Design Services  $210,065   $61,833   $1,098,234   $892,472 
Optical Components   1,479,322    250,405    4,428,409    774,429 
Medical Device Products and Assemblies   685,197    1,074,216    2,159,687    2,756,862 
Total Revenues  $2,374,584   $1,386,454   $7,686,330   $4,423,763 

 

Contract Assets and Liabilities

 

The nature of the Company’s products and services does not generally give rise to contract assets as it typically does not incur costs to fulfill a contract before a product or service is provided to a customer. The Company’s costs to obtain contracts are typically in the form of sales commissions paid to employees. The Company has elected to expense sales commissions associated with obtaining a contract as incurred as the amortization period is generally less than one year. These costs have been recorded in selling, general and administrative expenses. As of March 31, 2020, there were no contract assets recorded in the Company’s Consolidated Balance Sheets.

 

 

 

 11 

 

 

The Company’s contract liabilities arise as a result of unearned revenue received from customers at inception of contracts or where the timing of billing for services precedes satisfaction of our performance obligations. The Company generally satisfies performance obligations within one year from the contract inception date.

 

Contract liabilities, which were recorded as customer advances in the Company’s Consolidated Balance Sheets, and unearned revenue are comprised of the following:

 

   Three Months
Ended March 31,
   Nine Months
Ended March 31,
 
   2020   2019   2020   2019 
Contract liabilities, beginning of period  $388,506   $294,650   $450,192   $857,842 
Unearned revenue received from customers   41,874    61,928    334,893    81,684 
Revenue recognized   (119,855)   (97,650)   (474,560)   (680,598)
Contract liabilities, end of period  $310,525   $258,928   $310,525   $258,928 

 

6. BUSINESS ACQUISITION

 

On July 1, 2019 the Company acquired the operating assets of Ross Optical Industries, Inc. of El Paso, Texas, a supplier of custom and catalogue optical components sourced through an extensive network of worldwide specialized vendors and sold for industrial, military and medical applications. The acquisition had an effective date of June 1, 2019. All of Ross’ results of operations are included in our financial statements for the three- and nine-month periods ended March 31, 2020.

  

Consolidated unaudited actual and pro forma results of operations for the Company are presented below assuming that the acquisition of the Ross Optical division had occurred on July 1, 2018. Pro forma operating results include net adjustments resulting from the acquisition transaction.

 

   Three Months
Ended March 31,
   Nine Months
Ended March 31,
 
   2020   2019   2020   2019 
   (Actual)   (Pro Forma)   (Actual)   (Pro Forma) 
Revenues  $2,374,584   $2,413,438   $7,686,330   $7,348,803 
Net income (loss)   (466,130)   75,430    (1,103,065)   163,828 
Income (loss) per share                    
Basic  $(0.04)  $0.01   $(0.09)  $0.01 
Fully diluted  $(0.04)  $0.01   $(0.09)  $0.01 

 

Pro forma financial information is not necessarily indicative of the Company’s actual results of operations if the acquisition had been completed at the date indicated, nor is it necessarily an indication of future operating results. Amounts do not include any operating efficiencies or cost saving that the Company believes may become achievable over time.

 

 

 

 12 

 

 

7. COVID-19 PANDEMIC

 

The world-wide COVID-19 pandemic that began during the quarter ended March 31, 2020 and the domestic and international impact of policy decisions being made in major countries around the world has had, and is expected to have, an adverse impact on the Company’s sources of supply, current and future orders from the Company’s customers, collection of amounts owed to it from its customers, the Company’s internal operating procedures, and the Company’s overall financial condition. While the Company and many of its medical device and defense contracting customers continue to operate as essential businesses, the Company has taken various actions to augment its operating and human resource policies and procedures to guard against the potential health hazards of COVID-19. These augmented procedures can have a negative impact on the Company’s operational efficiencies. The Company sources various components from overseas suppliers throughout Asia, including China. The Company has experienced supply disruptions and customer delays, which it believes were the result of the COVID-19 pandemic and related economic slow-down. Given the uncertainty surrounding the continuation of economic slow-downs domestically and abroad, the Company cannot predict with certainty at this time what the future impact of COVID-19 and resulting business and economic policies in the US and abroad will be on its upcoming quarterly fiscal operating results.

 

8. SUBSEQENT EVENT

 

On April 14, 2020, the Company entered into agreements with accredited investors for the sale and purchase of 200,000 shares of its common stock, $0.01 par value at a purchase price of $1.25 per share. The Company received $250,000 in gross proceeds from the offering. The Company entered into this stock offering transaction in order to enhance its financial condition given uncertainties surrounding the COVID-19 pandemic and its potential impact on domestic and international sources of supply as well as the financial condition of its customers and the status of existing and future sales orders from them. The agreements also provide for the investors to receive additional shares of our common stock in the event the Company closes a subsequent offering of its common stock at a purchase price lower than $1.25 per share before April 14, 2021. The additional shares each investor would receive would be equal to the difference between the number of shares that would have been received at the reduced purchase price and the number of shares received at the $1.25 purchase price. The Company intends to use the proceeds from this placement for general working capital purposes.

 

In conjunction with the placement, the Company also entered into a registration rights agreement with the investors, whereby it is obligated to file a registration statement with the Securities Exchange Commission on or before 120 calendar days after April 14, 2020 to register the resale by the investors of 200,000 shares of our common stock purchased in the placement.

 

On May 6, 2020, the Company received loan proceeds in the amount of $808,962 under the Paycheck Protection Program, or PPP, from Bank of America. The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act, or CARES Act, provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The loans and accrued interest are forgivable after eight weeks as long as the Company uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and we maintain our payroll levels. The amount of loan forgiveness will be reduced if the Company terminates employees or reduces salaries during the eight-week period.

 

The unsecured loan, which is in the form of a note dated May 6, 2020, matures on May 6, 2022 and bears interest at a rate of 1% per annum, payable monthly commencing on December 6, 2020. The note may be prepaid at any time prior to maturity with no prepayment penalties. The Company intends to use the loan amount for eligible purposes, such as payroll expenses. While the Company currently believes that its use of the loan proceeds will meet the conditions for forgiveness of the loan, the Company cannot assure that it will be eligible for forgiveness, in whole or in part.

 

 

 

 13 

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

The following discussion of our financial condition and results of operations should be read in conjunction with the unaudited condensed consolidated financial statements and notes to those statements included elsewhere in this Quarterly Report on Form 10-Q for the quarter and nine months ended March 31, 2020 and with our audited consolidated financial statements for the year ended June 30, 2019 included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission on September 26, 2019.

 

This Quarterly Report on Form 10-Q contains forward-looking statements. When used in this report, the words “anticipate,” “suggest,” “estimate,” “plan,” “project,” “continue,” “ongoing,” “potential,” “expect,” “predict,” “believe,” “intend,” “may,” “will,” “should,” “could,” “would” and similar expressions are intended to identify forward-looking statements. You should not place undue reliance on these forward-looking statements.  Our actual results could differ materially from those anticipated in the forward-looking statements for many reasons, including the risks described in this report, the risks described in our Annual Report on Form 10-K for the year ended June 30, 2019 and other reports we file with the Securities and Exchange Commission. Although we believe the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made.  We do not intend to update any of the forward-looking statements after the date of this report to conform these statements to actual results or to changes in our expectations, except as required by law.

 

Overview

 

We have been a developer and manufacturer of advanced optical instruments since 1982. Our medical instrumentation line includes traditional endoscopes and endocouplers as well as other custom imaging and illumination products for use in minimally invasive surgical procedures. Much of our recent development efforts have been targeted at the development of next generation endoscopes. For the last ten years, we have funded internal research and development programs to develop next generation capabilities for designing and manufacturing 3D endoscopes and very small Microprecision™ lenses, anticipating future requirements as the surgical community continues to demand smaller and more enhanced imaging systems for minimally invasive surgery. 

 

Effective June 1, 2019 we acquired the operating assets of Ross Optical Industries, Inc. of El Paso, Texas, which we began operating as a division of our Company beginning on that date. The accompanying financial statements include the results of operations of the Ross Optical division for the entire nine and three-month periods ended March 31, 2020 and the assets and liabilities of the division as of June 30, 2019 and March 31, 2020. The acquisition of the assets of Ross Optical Industries effective June 1, 2019 expands our optics components and assemblies business. All products supplied by Ross Optical include a custom or catalog optic, which is sourced through Ross Optical’s extensive domestic and worldwide network of optical fabrication companies. Most systems make use of optical lenses, prisms, mirrors and windows and range from individual optical components to complex mechano-optical assemblies. Products often include thin film optical coatings that are applied using the in-house coating department. Approximately 75% of Ross Optical revenues are from customers in the United States, 8% from Western Europe and 7% from Canada during the nine months ended March 31, 2020. Ross Optical’s sales are mostly resale of specialized optical components with the remainder being assemblies. Ross Optical does not perform revenue generating engineering services or internal research and development. The majority of Ross Optical sales are for industrial applications with the remainder split between military and medical device products.

 

The Management Discussion and Analysis which follows is based on the financial condition and results of operations of our Company including the operating results for the three- and nine-month periods ended March 31, 2020 and the balance sheet as of June 30, 2019 and March 31, 2020 of our new division Ross Optical.

 

Our business is the design and manufacture of high-quality medical devices. Approximately 12% of our revenue in the nine months ended March 31, 2020 is from the design, manufacture and resale of optical products for military and defense and 31% is from other industrial, non-medical products. Our medical instrumentation line and unique design and manufacturing capabilities include traditional endoscopes and endocouplers as well as other custom imaging and illumination products for use in minimally invasive surgical procedures. We design and manufacture 3D endoscopes and very small Microprecision™ lenses, assemblies and complete medical devices to meet the surgical community’s continuing demand for smaller, disposable, and more enhanced imaging systems for minimally invasive surgery.

 

 

 

 14 

 

  

We are registered to the ISO 9001:2015 and ISO 13485:2016 Quality Standards and comply with the FDA Good Manufacturing Practices and the European Union Medical Device Directive for CE marking of our medical products.

 

Our internet websites are www.poci.com and www.rossoptical.com. Information on our website is not intended to be integrated into this report. Investors and others should note that we announce material financial information using our company websites (www.poci.com; www.rossoptical.com), our investor relations website, SEC filings, press releases, public conference calls and webcasts. Information about Precision Optics, our business, and our results of operations may also be announced by posts on the following social media channels:

 

  · Ross Optical's LinkedIn page (www.linkedin.com/company/ross-optical-industries/)
  · Ross Optical's Twitter feed (http://twitter.com/rossoptical)

 

The information that we post on these social media channels could be deemed to be material information. Therefore, we encourage investors, the media, and others interested in Precision Optics to review the information that we post on these social media channels. These social media channels may be updated from time to time on Precision Optics’ investor relations website. The information on, or accessible through, our websites and social media channels is not incorporated by reference in this Quarterly Report on Form 10-Q.

 

The markets in which we do business are highly competitive and include both foreign and domestic competitors. Many of our competitors are larger and have substantially greater resources than we do. Furthermore, other domestic or foreign companies, some with greater financial resources than we have, may seek to produce products or services that compete with ours. We routinely outsource specialized production efforts as required to obtain the most cost-effective production. Over the years and through the acquisition of the Ross Optical division in June 2019, we have developed extensive experience collaborating with other optical specialists worldwide.

  

We believe that our future success depends to a large degree on our ability to develop new optical products and services to enhance the performance characteristics and methods of manufacture of existing products. Accordingly, we expect to continue to seek and obtain product-related design and development contracts with customers and to selectively invest our own funds on research and development, particularly in the areas of Microprecision™ optics, micro medical cameras, illumination, single-use endoscopes and 3D endoscopes.

 

The Ross Optical division sales are primarily optical components and assemblies for industrial applications in addition to medical and military uses. By combining the unique capabilities of our Company with the Ross Optical division we believe there are opportunities for expanded sales of each division products and services throughout the combined customer base. Additionally, we believe Ross’ expanded worldwide vendor relationships will benefit our traditional efforts to source materials at competitive prices for our development projects and manufacturing activities.

   

For the nine months ended March 31, 2020, approximately 23% of our sales were made to our three largest customers representing 10%, 7% and 7% of our total sales, respectively. No other customer accounted for more than 4% our total sales during the nine months ended March 31, 2020. Our three largest customers during the quarter ended March 31, 2020 are all in the medical device industry. One represents engineering service revenue for an early-stage company, and the other two represent production revenue for companies commercializing a cardiovascular endoscope and an ENT scanning device. Each of these three products incorporates our Microprecision™ technologies as enabling design features. In addition to the three largest customers, we made sales to two hundred ninety-three other customers during the nine-month period ended March 31, 2020. 

 

Current sales and marketing activities are intended to broaden awareness of the benefits of our new technology platforms and our successful application of these new technologies to medical device projects requiring surgery-grade visualization from sub-millimeter sized devices and 3D endoscopy, including single-use products and assemblies. We market directly to established medical device companies primarily in the United States that we believe could benefit from our advanced endoscopy visualization systems. Through this direct marketing, referrals, attendance at trade shows and a presence in online professional association websites, we have expanded our on-going pipeline of projects to significant medical device companies as well as well-funded emerging technology companies. We expect our customer pipeline to continue to expand as development projects transition to production orders and new customer projects enter the development phase. Our Ross Optical division markets through existing customers and trade shows, in addition to proactive online marketing strategies executed primarily through its website. We believe there are opportunities to expand the reach of sales activities of our business and that of our new division, Ross Optical, through the gradual integration of some of the sales and marketing resources of the two operations.

 

 

 

 15 

 

 

General

 

This management’s discussion and analysis of financial condition and results of operations is based upon our unaudited consolidated financial statements, which have been prepared without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

  

There have been no significant changes in our critical accounting policies as disclosed in the Notes to our Financial Statements contained in our Annual Report on Form 10-K for the year ended June 30, 2019 filed with the Securities and Exchange Commission on September 26, 2019.

 

Results of Operations

 

Our total revenues for the quarter ended March 31, 2020, were $2,374,584, as compared to $1,386,454 for the same period in the prior year, an increase of $988,130, or 71.3%. Revenues increased during the quarter ended March 31, 2020 compared to the same quarter of the prior year primarily due to the revenues of the Ross Optical division, which were $1,212,805 for the quarter ended March 31, 2020. Our non-Ross revenues decreased by $224,675 during the quarter ended March 31, 2020 from their levels in the same period of the prior year. While the overall sales were negatively impacted by the COVID-19 pandemic, the mix of engineering service, production and component sales were similar between the quarters.

 

The COVID-19 world-wide pandemic that began during the quarter ended March 31, 2020 and the domestic and international impact of policy decisions being made in major countries around the world has had, and is expected to have, an adverse impact on our sources of supply, current and future orders from our customers, collection of amounts owed to us from our customers, our internal operating procedures, and our overall financial condition. While we and many of our medical device and defense contracting customers continue to operate as essential businesses, we have taken various actions to augment our operating and human resource policies and procedures to guard against the potential health hazards of COVID-19. These augmented procedures can have a negative impact on our operational efficiencies. We source various components from overseas suppliers throughout Asia, including China. During the quarter ended March 31, 2020, certain suppliers from China accelerated shipments to our Ross division in anticipation of pending shutdowns, which had a beneficial effect on our Ross sales. On the other hand, we also had supply disruptions and customer delays during the quarter causing the decrease in non-Ross sales mentioned above, which we believe were the result of the COVID-19 pandemic and related economic slow-down. We continue to communicate as closely as possible with our suppliers and customers to maintain a current perspective on the future effects of COVID-19 on our business. Given the uncertainty surrounding the continuation of economic slow-downs domestically and abroad, we cannot predict with certainty at this time what the future impact of COVID-19 and resulting business and economic policies in the US and abroad will be on our up-coming quarterly fiscal operating results.

 

Our total revenues for the nine months ended March 31, 2020 were $7,686,330, as compared to $4,423,763 for the same period in the prior year, an increase of $3,262,567, or 73.8%. Revenues increased during the nine months ended March 31, 2020 compared to the same period of the prior year primarily due to the revenues of the Ross Optical division, which were $3,454,493 for the nine months ended March 31, 2020. Our non-Ross revenues decreased by $191,926 during the nine months ended March 31, 2020 from their levels in the same period of the prior year primarily as a result of the COVID-19 pandemic effects on the quarter ended March 31, 2020 as described above. While the overall sales were negatively impacted by the COVID-19 pandemic, the mix of engineering service, production and component sales were similar during the quarters.

 

 

 

 16 

 

    

Gross profit for the quarter ended March 31, 2020 was $817,019, compared to $455,936 for the same period in the prior year, reflecting an increase of $361,083, or 79.2%. Gross profit for the quarter ended March 31, 2020 as a percentage of our revenues was 34.4%, an increase from the gross profit percentage of 32.9% for the same period in the prior year. Gross profit for the nine months ended March 31, 2020 was $2,709,075, as compared to $1,274,165 for the same period in the prior year, which reflects an increase of $1,434,910 or 112.6%. Gross profit for the nine months ended March 31, 2020 as a percentage of our revenues was 35.2%, an increase from the gross profit percentage of 28.8% for the same period in the prior year. Quarterly gross profit and gross profit percentage depend on a number of factors, including overall sales volume, facility utilization, product sales mix, the costs of engineering services, production start-up costs, challenges in connection with new products, the effects of COVID-19 pandemic policy decisions on various economies and our suppliers and customers, as well as the effects on production efficiencies due to the augmented policies we have incorporated into our operations as a result of the COVID-19 pandemic.

 

The increase in gross profit dollars and gross profit percentage during the quarter and nine-month period ended March 31, 2020 compared to the same periods of the prior year was primarily due to the inclusion of the Ross Optical division revenue at a higher gross margin percentage than we realize on non-Ross revenues. Ross Optical division revenues generated a gross margin percentage of 48-50% while non-Ross revenue margin was 24.0% for the nine months ended March 31, 2020. The non-Ross gross margin is dependent on a number of factors and is expected to fluctuate from quarter to quarter based on the nature and status of engineering projects. Specifically, periodic margins are impacted by revenue volume, facility utilization, product sales mix, and unanticipated cost over-runs associated with engineering projects, start-up production activities of new products, and the effects of COVID-19 pandemic policy decisions on various economies and our suppliers and customers as well as the effects on production efficiencies of the augmented policies we have incorporated into our operations as a result of the COVID-19 pandemic. During the quarter ended March 31, 2020, a non-Ross engineering service project experienced cost over-runs that negatively impacted gross margins during the period and due to timing of milestone deliverables generated no revenue. The project negatively impacted the consolidated gross margin percentage by 3.3% during the quarter ended March 31, 2020. The cost over-runs resulted from design challenges and issues we are addressing and that we believe will only cause a temporary decrease in total realized gross margins. The remainder of our production and engineering jobs resulted in margins within our targeted range with reasonably expected fluctuations.

 

Research and development expenses were $319,875 for the quarter ended March 31, 2020, compared to $121,640 for the same period in the prior year, an increase of $198,235, or 163.0%. Research and development expenses were $700,605 for the nine months ended March 31, 2020, compared to $347,851 for the same period in the prior year, an increase of $352,754, or 101.4%. In-house research and development and certain internal functions not directly related to customer engagements are classified as research and development expenses with the majority of our engineering, research and development activities being consumed in revenue generating engagements with our customers for the development of their products. During the quarter ended March 31, 2020 we had a larger staff of engineering personnel and a greater amount of our engineering personnel time was consumed in internal research and development activities; the product of which we believe will benefit various engineering design projects involving specialized fixturing and illumination features.

  

Selling, general and administrative expenses were $962,591 for the quarter ended March 31, 2020, compared to $414,475 for the same period in the prior year, an increase of $548,116, or 132.2%. The increase in the quarter ended March 31, 2020, compared to the same quarter of the prior fiscal year was due to the addition of $320,888 of selling, general and administrative expenses incurred by our Ross Optical division. Non-Ross selling, general and administrative expenses reflect a $42,508 increase in stock-based compensation and service fees in the quarter ended March 31, 2020 compared to the same period of the prior year, and increases of $184,720 in compensation to existing and newly hired employees, advertising, tradeshows and professional fees.

 

Selling, general and administrative expenses were $3,111,397 for the nine months ended March 31, 2020, compared to $1,430,880 for the same period in the prior year, an increase of $1,680,517, or 117.4%. The increase in the nine months ended March 31, 2020, compared to the same nine-month period of the prior fiscal year was due to the addition of $919,930 of selling, general and administrative expenses incurred by our Ross Optical division. Non-Ross selling, general and administrative expenses reflect a $2,505 decrease in stock-based compensation and service fees in the nine months ended March 31, 2020 compared to the same period of the prior year, and increases of $763,092 driven by higher compensation to existing and newly hired employees, advertising, tradeshows and professional fees.

 

 17 

 

 

Liquidity and Capital Resources

 

We have sustained recurring net losses for several years. During the year ended June 30, 2019 and the nine months ended March 31, 2020 we incurred net losses of $614,871 and $1,103,065, respectively. As a result of our acquisition of the Ross Optical division, our revenue, gross margin and components of our working capital have increased. At March 31, 2020 cash was $632,131, accounts receivables were $1,479,077 and current liabilities were $2,454,280, including $310,525 of customer advances received for future order deliveries.

 

Although our financial performance has improved during the last few fiscal quarters, our operating expenses have also increased and we continue to experience pricing pressure from our customers and challenges in engineering projects and production orders that result in cost over-runs and depressed gross margins. Consequently, critical to our ability to maintain our financial condition is achieving and maintaining a level of quarterly revenues that generate break even or better financial performance as well as timely collection of accounts receivable from our customers. We believe profitable operating results can be achieved through a combination of revenue levels, realized gross margins and controlling operating expense increases, all of which are subject to periodic fluctuations resulting from sales mix and the stage of completion of varying engineering service projects as they progress towards and into production level revenues.

 

We have traditionally funded working capital needs through product sales, management of working capital components of our business, cash received from public and private offerings of our common stock, warrants to purchase shares of our common stock or convertible notes, and by customer advances paid against purchase orders and recorded in the current liabilities section of the accompanying financial statements. Our management believes that the opportunities represented by our current production projects and engineering pipeline of Microprecision™ optical elements, micro medical camera assemblies and 3D endoscope projects have the potential to generate increasing revenues and profitable financial results.

 

Although we believe the fundamentals of our operations, business plans and opportunities can generate profitable financial results, the effects of the COVID-19 pandemic have resulted in a reduced level of sales in the quarter ended March 31, 2020 and an increase in our net loss. To enhance our financial condition and our ability to manage future uncertainties resulting from COVID-19 and its effects, in April 2020 we entered into agreements with accredited investors for the sale of 200,000 shares of our common stock at $1.25 per share which generated $250,000 of proceeds available for general working capital purposes.

 

On May 6, 2020, we received loan proceeds in the amount of $808,962 under the Paycheck Protection Program, or PPP, from Bank of America. The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act, or CARES Act, provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The loans and accrued interest are forgivable after eight weeks as long as we use the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and we maintain our payroll levels. The amount of loan forgiveness will be reduced if we terminate employees or reduce salaries during the eight-week period.

 

The unsecured loan, which is in the form of a note dated May 6, 2020, matures on May 6, 2022 and bears interest at a rate of 1% per annum, payable monthly commencing on December 6, 2020. The note may be prepaid at any time prior to maturity with no prepayment penalties. We intend to use the loan amount for eligible purposes, such as payroll expenses. While we currently believe that our use of the loan proceeds will meet the conditions for forgiveness of the loan, we cannot assure you that it will be eligible for forgiveness, in whole or in part.

 

Capital equipment expenditures and additional patent costs during the nine months ended March 31, 2020 were $142,833 and we acquired an additional $113,213 of manufacturing equipment under two capitalized leases during the quarter ended March 31, 2020. Future capital equipment expenditures will be dependent upon the type and amount of future sales revenue and the needs of on-going research and development efforts.

 

We have contractual cash commitments related to open purchase orders as of March 31, 2020 of approximately $830,402, plus a $108,437 commitment remaining under three capital lease obligations for the acquisition of equipment and $139,791 commitment remaining under a three-year facility lease relating the Ross Optical division in El Paso, Texas (see Note 3. Lease Obligations). We have no other contractual cash commitments since other leased facilities are currently on a month-to-month basis.

 

 

 

 18 

 

 

Off-Balance Sheet Arrangements

 

We currently have no off-balance sheet arrangements that have, or are reasonably likely to have, a current or future material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

As a smaller reporting company, as defined by Rule 12b-2 of the Exchange Act and in Item 10(f)(1) of Regulation S-K, we are electing scaled disclosure reporting obligations and therefore are not required to provide the information requested by this Item.

  

Item 4. Controls and Procedures.

 

Management’s Evaluation of Disclosure Controls and Procedures

 

Our Chief Executive Officer and our Chief Financial Officer evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures, including internal control over financial reporting, were not effective, as of March 31, 2020, to ensure the information we are required to disclose in reports that we file or submit under the Securities Exchange Act of 1934, as amended (i) is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and forms, and (ii) is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Our disclosure controls and procedures are intended to be designed to provide reasonable assurance that such information is accumulated and communicated to our management. Based on this evaluation, our management concluded that our internal control over financial reporting was not effective as of March 31, 2020.

  

The following is a description of two material weaknesses in our internal control over financial reporting:

 

Segregation of Duties: As previously disclosed in our Annual Reports on Form 10-K for the fiscal years ended June 30, 2008-2019, our management identified a control deficiency during the 2008 fiscal year because we lacked sufficient staff to segregate accounting duties. We believe the control deficiency resulted primarily because we have the equivalent of one and one-half persons performing all accounting-related on-site duties. As a result, we did not maintain adequate segregation of duties within our critical financial reporting applications, the related modules and financial reporting processes. This control deficiency could result in a misstatement of balance sheet and income statement accounts in our interim or annual consolidated financial statements that would not be detected. Accordingly, management has determined that this control deficiency constitutes a material weakness. During the period beginning with fiscal year 2008 through June 30, 2019, no audit adjustments resulting from this condition were required.

 

To address and remediate the material weakness in internal control over financial reporting described above, beginning with the quarter ended September 30, 2008, we instituted a procedure whereby our Chief Executive Officer, our Chief Financial Officer and other members of our Board of Directors perform a higher level review of the quarterly and annual reports on Form 10-Q and Form 10-K prior to filing.

 

 

 

 19 

 

 

We believe that the step outlined above strengthens our internal control over financial reporting and mitigates the material weakness described above. As part of our assessment of internal control over financial reporting for the fiscal year ended June 30, 2019, our management has evaluated this additional control and has determined that it is operating effectively.

 

Inventory Valuation: As previously disclosed in our Annual Report on Form 10-K for the fiscal year ended June 30, 2019, we reported a material weakness with respect to the valuation of our inventories. Specifically, the amounts used to value our inventory at June 30, 2009 with respect to overhead rates and purchased items were often inconsistent with the supporting documentation, due to year-to-year changes in overhead rates and costs of purchased items that were not properly reflected in inventory valuation. Accordingly, management had determined that this control deficiency constituted a material weakness as of June 30, 2009. Periodic fiscal year end audit adjustments of approximately $50,000 have been necessary as a result of this condition.

 

To address and remediate the material weakness in internal control over financial reporting described above, beginning in the quarter ended September 30, 2009 and continuing through the quarter ended March 31, 2020, we implemented processes to improve our inventory controls and documentation surrounding inventory valuation for overhead rates, and performed procedures to ensure that the pricing of inventory items was consistent with the supporting documentation. We believe that the step outlined above strengthens our internal control over financial reporting and mitigates the material weakness described above.

   

Changes in Internal Control over Financial Reporting

 

There was no change in our internal control over financial reporting that occurred during the first quarter of our fiscal year covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

We intend to continue to remediate material weaknesses and enhance our internal controls but cannot guarantee that our efforts will result in remediation of our material weaknesses or that new issues will not be exposed in this process.

  

 

 

 

 

 

 

 

 

 

 

 

 20 

 

 

PART II. OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

Our Company, on occasion, may be involved in legal matters arising in the ordinary course of our business. While management believes that such matters are currently insignificant, matters arising in the ordinary course of business for which we are or could become involved in litigation may have a material adverse effect on our business, financial condition or results of operations. We are not aware of any pending or threatened litigation against us or our officers and directors in their capacity as such that could have a material impact on our operations or finances.

 

Item 1A. Risk Factors.

 

Other than as described below, there have been no material changes from the risk factors previously disclosed in our annual report on Form 10-K for the fiscal year ended June 30, 2019, as filed with the Securities and Exchange Commission on September 26, 2019, and the quarterly report on Form 10-Q for the quarter ended December 31, 2019, as filed on February 13, 2020.

 

The COVID-19 world-wide pandemic and the economic effects of governmental entities and commercial business policy decisions relating to it could cause disruptions with our sources of supply and customer orders and their ability to pay amounts owed us.

 

The COVID-19 world-wide pandemic that began during the quarter ended March 31, 2020 and the domestic and international impact of policy decisions being made in major countries around the world has had, and is expected to have, an adverse impact on our sources of supply, current and future orders from our customers, collection of amounts owed to us from our customers, our internal operating procedures, and our overall financial condition. While we and many of our medical device and defense contracting customers continue to operate as essential businesses, we have taken various actions to augment our operating and human resource policies and procedures to guard against the potential health hazards of COVID-19. These augmented procedures can have a negative impact on our operational efficiencies. We source various components from overseas suppliers throughout Asia, including China. We have experienced supply disruptions and customer delays, which we believe was the result of the COVID-19 pandemic and related economic slow-down. Given the uncertainty surrounding the continuation of economic slow-downs domestically and abroad, we cannot predict with certainty at this time what the future impact of COVID-19 and resulting business and economic policies in the US and abroad will be on our upcoming quarterly fiscal operating results.

   

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

On April 14, 2020, we entered into agreements with accredited investors for the sale and purchase of 200,000 shares of our common stock, $0.01 par value at a purchase price of $1.25 per share. We received $250,000 in gross proceeds from the offering. The agreements also provide for the investors to receive additional shares of our common stock in the event we have a subsequent offering of our common stock at a purchase price lower than $1.25 per share before April 14, 2021. The additional shares an investor would receive would be equal to the difference between the number of shares that would have been received at the reduced purchase price and the number of shares received at the $1.25 purchase price. We intend to use the proceeds from this placement for general working capital purposes.

 

In conjunction with the placement, we also entered into a registration rights agreement with the investors, whereby we are obligated to file a registration statement with the Securities Exchange Commission on or before 120 calendar days after April 14, 2020 to register the resale by the investors of 200,000 shares of our common stock purchased in the placement.

 

We relied on the Section 4(a)(2) exemption from securities registration under the federal securities laws for transactions not involving any public offering. No advertising or general solicitation was employed in offering the securities. The securities were issued to accredited investors. The securities were offered for investment purposes only and not for the purpose of resale or distribution. The transfer thereof was appropriately restricted by us.

 

 

 

 21 

 

 

Item 3. Defaults Upon Senior Securities.

 

Not applicable.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

Item 5. Other Information.

 

On April 14, 2020, we entered into agreements with accredited investors for the sale and purchase of 200,000 shares of our common stock, $0.01 par value at a purchase price of $1.25 per share. We received $250,000 in gross proceeds from the offering. The agreements also provide for the investors to receive additional shares of our common stock in the event we close a subsequent offering of our common stock at a purchase price lower than $1.25 per share before April 14, 2021. The additional shares an investor would receive would be equal to the difference between the number of shares that would have been received at the reduced purchase price and the number of shares received at the $1.25 purchase price. We intend to use the proceeds from this placement for general working capital purposes.

 

In conjunction with the placement, we also entered into a registration rights agreement with the investors, whereby we are obligated to file a registration statement with the Securities Exchange Commission on or before 120 calendar days after April 14, 2020 to register the resale by the investors of 200,000 shares of our common stock purchased in the placement.

 

On May 6, 2020, we received loan proceeds in the amount of $808,962 under the Paycheck Protection Program, or PPP, from Bank of America. The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act, or CARES Act, provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The loans and accrued interest are forgivable after eight weeks as long as we use the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and we maintain our payroll levels. The amount of loan forgiveness will be reduced if we terminate employees or reduce salaries during the eight-week period.

 

The unsecured loan, which is in the form of a note dated May 6, 2020, matures on May 6, 2022 and bears interest at a rate of 1% per annum, payable monthly commencing on December 6, 2020. The note may be prepaid at any time prior to maturity with no prepayment penalties. We intend to use the loan amount for eligible purposes, such as payroll expenses. While we currently believe that our use of the loan proceeds will meet the conditions for forgiveness of the loan, we cannot assure you that it will be eligible for forgiveness, in whole or in part.

 

One of our largest customers has delayed deliveries on its existing orders for endoscopes manufactured by us, due to the impact of COVID-19. In response to the elimination of elective surgeries over the last several months we have agreed with our customer to reduce monthly deliveries from 75 units a month to 20 units per month from May 1, 2020 until February 28, 2021. This reduction will have a revenue impact of approximately $190,000 per quarter. We anticipate that delivery rates will return back to the original contract levels of 75 units per month in the third fiscal quarter of 2021. The total number of units on the purchase order remains unchanged.

 

 

 22 

 

 

Item 6. Exhibits.

 

Exhibit   Description
     
2.1   Asset Purchase Agreement between the Company and Optometrics Corporation, dated January 18, 2008 (included as Exhibit 2.1 to the Form 8-K filed January 25, 2008, and incorporated herein by reference).
     
3.1   Articles of Organization of Precision Optics Corporation, Inc., as amended (included as Exhibit 3.1 to the Form SB-2 filed March 16, 2007, and incorporated herein by reference).
     
3.2   Bylaws of Precision Optics Corporation, Inc. (included as Exhibit 3.2 to the Form S-1 filed December 18, 2008, and incorporated herein by reference).
     
3.3   Articles of Amendment to the Articles of Organization of Precision Optics Corporation, Inc., dated November 25, 2008 and effective December 11, 2008 (included as Exhibit 3.1 to the Form 8-K filed December 11, 2008, and incorporated herein by reference).
     
3.4   Amended and Restated Bylaws of Precision Optics Corporation, Inc. (included as Exhibit 3.1 to the Current Report on Form 8-K filed July 11, 2014, and incorporated herein by reference).
     
10.1   Precision Optics Corporation, Inc. 2011 Equity Incentive Plan, dated October 13, 2011 (included as Exhibit 10.2 to Form S-8 filed October 14, 2011, and incorporated herein by reference.)
     
10.2   Precision Optics Corporation, Inc. Amended 2011 Equity Incentive Plan, dated October 14, 2011, as amended on April 16, 2015 (included as Exhibit 10.1 to the Company’s Registration Statement on Form S-8 filed April 20, 2015, and incorporated herein by reference).
     
10.3   Consulting Agreement by and between the Company and Donald A. Major, dated June 15, 2016 (included as Exhibit 10.1 to the Form 8-K filed on June 23, 2016, and incorporated herein by reference).
     
10.4   Form of Securities Purchase Agreement, by and among the Company and the Investors, dated November 22, 2016 (included as Exhibit 10.1 to the Form 8-K filed November 29, 2016, and incorporated herein by reference).
     
10.5   Form of Registration Rights Agreement, by and among the Company and the Investors, dated November 22, 2016 (included as Exhibit 10.2 to the Form 8-K filed on November 29, 2016, and incorporated herein by reference).
     
10.6   Form of Securities Purchase Agreement, by and the Company and the Investors, dated August 22, 2017 (included as Exhibit 10.1 to the Form 8-K filed on August 25, 2017, and incorporated herein by reference).
     
10.7   Form of Registration Rights Agreement, by and among the Company and the Investors, dated August 22, 2017 (included as Exhibit 10.2 to the Form 8-K filed on August 25, 2017, and incorporated herein by reference).
     
10.8   Compensation Agreement, by and between the Company and Joseph N. Forkey, dated August 2, 2018 (included as Exhibit 10.1 to the Form 8-K filed on August 3, 2018, and incorporated herein by reference).

 

 

 

 23 

 

 

10.9   Offer letter by and between the Company and Donald A. Major, dated August 2, 2018 (included as Exhibit 10.9 to the Form 10-K filed on September 27, 2018, and incorporated herein by reference).
     
10.10   Form of Securities Purchase Agreement by and among the Company and the Investors, dated October 16, 2018 (included as Exhibit 10.1 to the Form 8-K filed on October 18, 2018, and incorporated herein by reference).

 

10.11   Form of Registration Rights Agreement by and among the Company and the Investors, dated October 16, 2018 (included as Exhibit 10.2 to the Form 8-K filed on October 18, 2018, and incorporated herein by reference).
     
10.12†+   Asset Purchase Agreement dated July 1, 2019, between Precision Optics Corporation, Inc. and Ross Optical Industries, Inc. and the shareholders (included as Exhibit 10.1 to the Form 8-K filed on July 8, 2019, and incorporated herein by reference).
     
10.13   Form of Purchase Agreement, by and among Precision Optics Corporation, Inc. and several Investors, dated July 1, 2019 (included as Exhibit 10.2 to the Form 8-K filed on July 8, 2019, and incorporated herein by reference).
     
10.14   Form of Registration Rights Agreement, by and among Precision Optics Corporation, Inc. and several Investors, dated July 1, 2019 (included as Exhibit 10.3 to the Form 8-K filed on July 8, 2019, and incorporated herein by reference).
     
10.15   Employment Agreement, by and among Precision Optics Corporation. Inc. and Divaker Mangadu, dated July 1, 2019 (included as Exhibit 10.4 to the Form 8-K filed on July 8, 2019, and incorporated herein by reference).
     
10.16†   Employment Agreement, by and among Precision Optics Corporation, Inc. and Jeff DiRubio, dated April 26, 2019 (included as Exhibit 10.16 to the annual report on Form 10-K filed on September 26, 2019, and incorporated herein by reference).
     
10.17+   Lease Agreement, by and among Precision Optics Corporation, Inc. and Texzona Industries Ltd. dated July 1, 2019 (included as Exhibit 10.17 to the annual report on Form 10-K filed on September 26, 2019, and incorporated herein by reference).
     
10.18*   Employment Offer Letter Daniel S. Habhegger, dated December 2, 2019 (included as Exhibit 10.18 to the quarterly report on Form 10-Q filed on February 13, 2020, and incorporated herein by reference).
     
10.19   Form of Securities Purchase Agreement, by and among Precision Optics Corporation, Inc. and several Investors, dated April 14, 2020 (included as Exhibit 10.1 to the current report on Form 8-K filed on May 7, 2020, and incorporated herein by reference).
     
10.20   Form of Registration Rights Agreement, by and among Precision Optics Corporation, Inc. and several Investors, dated April 14, 2020 (included as Exhibit 10.2 to the current report on Form 8-K filed on May 7, 2020, and incorporated herein by reference).
     
14.1   Precision Optics Corporation, Inc. Corporate Code of Ethics and Conduct (included as Exhibit 14.1 to the Form 10-K filed September 28, 2008, and incorporated herein by reference).

 

 

 

 24 

 

 

31.1*   Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     
31.2*   Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     
32.1*   Certification of Officers pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

101.INS*   XBRL Instance Document
     
101.SCH*   XBRL Taxonomy Extension Schema Document
     
101.CAL*   XBRL Taxonomy Extension Calculation Linkbase Document
     
101.DEF*   XBRL Taxonomy Extension Definition Linkbase Document
     
101.LAB*   XBRL Taxonomy Extension Label Linkbase Document
     
101.PRE*   XBRL Taxonomy Extension Presentation Linkbase Document

 

* Filed herewith.

 

  Certain portions of the agreement have been omitted to preserve the confidentiality of such information. The Company will furnish copies of any such information to the SEC upon request.

 

+   The schedules to agreement have been omitted from this filing pursuant to Item 601(a)(5) of Regulation S-K.  The Company will furnish copies of any such schedules to the SEC upon request.

 

Copies of above exhibits not contained herein are available to any stockholder, upon written request to: Chief Financial Officer, Precision Optics Corporation, Inc., 22 East Broadway, Gardner, MA 01440.

 

 

 

 25 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  PRECISION OPTICS CORPORATION, INC.
     
Date: May 14, 2020 By: /s/ Joseph N. Forkey
    Joseph N. Forkey
   

Chief Executive Officer

(Principal Executive Officer)

     
     
Date: May 14, 2020 By: /s/ Daniel S. Habhegger
    Daniel S. Habhegger
   

Chief Financial Officer 

(Principal Financial Officer and Principal Accounting Officer)

 

 

 

 

 

 

 

 

 

 

 

 

 

 26 

 

 

EX-31.1 2 precision_10q-ex3101.htm CERTIFICATION

Exhibit 31.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

 

I, Joseph N. Forkey, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Precision Optics Corporation, Inc. for the quarter ended March 31, 2020;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

  By: /s/ Joseph N. Forkey
Date: May 14, 2020   Joseph N. Forkey
    Chief Executive Officer
    (Principal Executive Officer)

 

EX-31.2 3 precision_10q-ex3102.htm CERTIFICATION

Exhibit 31.2

   

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

 

I, Daniel S. Habhegger, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Precision Optics Corporation, Inc. for the quarter ended March 31, 2020;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

  By: /s/ Daniel S. Habhegger
Date: May 14, 2020   Daniel S. Habhegger
   

Chief Financial Officer 

(Principal Financial Officer and Principal Accounting Officer)

 

EX-32.1 4 precision_10q-ex3201.htm CERTIFICATION

Exhibit 32.1

 

CERTIFICATION OF OFFICERS PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

 

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officers of Precision Optics Corporation, Inc., a Massachusetts corporation (the “Company”), do hereby certify, to such officers’ knowledge, that:

 

The Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: May 14, 2020 By: /s/ Joseph N. Forkey
    Joseph N. Forkey
    Chief Executive Officer
    (Principal Executive Officer)
     
     
Date: May 14, 2020 By: /s/ Daniel S. Habhegger
    Daniel S. Habhegger
   

Chief Financial Officer 

(Principal Financial Officer and Principal Accounting Officer)

    /s/ Daniel S. Habhegger

 

A signed original of this written statement required by Section 906 has been provided to Precision Optics Corporation, Inc. and will be retained by Precision Optics Corporation, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

 

 

 

 

 

 

 

 

EX-101.INS 5 peye-20200331.xml XBRL INSTANCE FILE 0000867840 2018-06-30 0000867840 2019-06-30 0000867840 PEYE:Option1Member 2019-07-01 2020-03-31 0000867840 PEYE:Option2Member 2019-07-01 2020-03-31 0000867840 PEYE:Option3Member 2019-07-01 2020-03-31 0000867840 PEYE:Option4Member 2019-07-01 2020-03-31 0000867840 PEYE:Option5Member 2019-07-01 2020-03-31 0000867840 PEYE:Option6Member 2019-07-01 2020-03-31 0000867840 PEYE:Option7Member 2019-07-01 2020-03-31 0000867840 PEYE:Option8Member 2019-07-01 2020-03-31 0000867840 PEYE:Option9Member 2019-07-01 2020-03-31 0000867840 PEYE:Option10Member 2019-07-01 2020-03-31 0000867840 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-07-01 2020-03-31 0000867840 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-07-01 2019-03-31 0000867840 us-gaap:CostOfSalesMember 2019-07-01 2020-03-31 0000867840 us-gaap:CostOfSalesMember 2018-07-01 2019-03-31 0000867840 us-gaap:ResearchAndDevelopmentExpenseMember 2019-07-01 2020-03-31 0000867840 us-gaap:ResearchAndDevelopmentExpenseMember 2018-07-01 2019-03-31 0000867840 PEYE:Option11Member 2019-07-01 2020-03-31 0000867840 us-gaap:StockOptionMember 2019-07-01 2020-03-31 0000867840 PEYE:Option12Member 2019-07-01 2020-03-31 0000867840 PEYE:Option13Member 2019-07-01 2020-03-31 0000867840 2019-07-01 2020-03-31 0000867840 2020-03-31 0000867840 2019-03-31 0000867840 PEYE:Option1Member 2020-03-31 0000867840 PEYE:Option2Member 2020-03-31 0000867840 PEYE:Option3Member 2020-03-31 0000867840 PEYE:Option4Member 2020-03-31 0000867840 PEYE:Option5Member 2020-03-31 0000867840 PEYE:Option6Member 2020-03-31 0000867840 PEYE:Option7Member 2020-03-31 0000867840 PEYE:Option8Member 2020-03-31 0000867840 PEYE:Option10Member 2020-03-31 0000867840 PEYE:Option11Member 2020-03-31 0000867840 PEYE:Option12Member 2020-03-31 0000867840 PEYE:Option13Member 2020-03-31 0000867840 us-gaap:StockOptionMember 2020-03-31 0000867840 PEYE:Option9Member 2020-03-31 0000867840 us-gaap:StockOptionMember 2019-06-30 0000867840 2016-01-31 0000867840 2018-07-01 2019-03-31 0000867840 PEYE:EngineeringDesignServicesMember 2019-07-01 2020-03-31 0000867840 PEYE:EngineeringDesignServicesMember 2018-07-01 2019-03-31 0000867840 PEYE:OpticalComponentsMember 2019-07-01 2020-03-31 0000867840 PEYE:OpticalComponentsMember 2018-07-01 2019-03-31 0000867840 PEYE:MedicalDeviceMember 2019-07-01 2020-03-31 0000867840 PEYE:MedicalDeviceMember 2018-07-01 2019-03-31 0000867840 us-gaap:CommonStockMember 2018-06-30 0000867840 us-gaap:CommonStockMember 2019-03-31 0000867840 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0000867840 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000867840 us-gaap:RetainedEarningsMember 2018-06-30 0000867840 us-gaap:RetainedEarningsMember 2019-03-31 0000867840 us-gaap:CommonStockMember 2019-06-30 0000867840 us-gaap:CommonStockMember 2020-03-31 0000867840 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000867840 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000867840 us-gaap:RetainedEarningsMember 2019-06-30 0000867840 us-gaap:RetainedEarningsMember 2020-03-31 0000867840 srt:ProFormaMember 2018-07-01 2019-03-31 0000867840 us-gaap:CommonStockMember srt:ChiefExecutiveOfficerMember 2018-07-01 2018-08-02 0000867840 us-gaap:CommonStockMember srt:ChiefExecutiveOfficerMember 2018-07-01 2018-09-30 0000867840 2020-05-14 0000867840 2020-01-01 2020-03-31 0000867840 2019-01-01 2019-03-31 0000867840 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0000867840 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0000867840 us-gaap:CommonStockMember 2018-12-31 0000867840 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2018-09-30 0000867840 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000867840 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000867840 us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0000867840 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000867840 us-gaap:RetainedEarningsMember 2018-12-31 0000867840 2018-07-01 2018-09-30 0000867840 2018-12-31 0000867840 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0000867840 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000867840 us-gaap:CommonStockMember 2019-12-31 0000867840 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0000867840 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000867840 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000867840 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0000867840 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000867840 us-gaap:RetainedEarningsMember 2019-12-31 0000867840 2019-07-01 2019-09-30 0000867840 2019-12-31 0000867840 us-gaap:CostOfSalesMember 2020-01-01 2020-03-31 0000867840 us-gaap:CostOfSalesMember 2019-01-01 2019-03-31 0000867840 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0000867840 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-03-31 0000867840 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-03-31 0000867840 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-03-31 0000867840 PEYE:EngineeringDesignServicesMember 2020-01-01 2020-03-31 0000867840 PEYE:EngineeringDesignServicesMember 2019-01-01 2019-03-31 0000867840 PEYE:OpticalComponentsMember 2020-01-01 2020-03-31 0000867840 PEYE:OpticalComponentsMember 2019-01-01 2019-03-31 0000867840 PEYE:MedicalDeviceMember 2020-01-01 2020-03-31 0000867840 PEYE:MedicalDeviceMember 2019-01-01 2019-03-31 0000867840 srt:ProFormaMember 2019-01-01 2019-03-31 0000867840 us-gaap:CommonStockMember 2018-10-01 2018-12-31 0000867840 us-gaap:CommonStockMember 2019-10-01 2019-12-31 0000867840 us-gaap:CommonStockMember 2018-09-30 0000867840 us-gaap:CommonStockMember 2019-09-30 0000867840 us-gaap:AdditionalPaidInCapitalMember 2018-10-01 2018-12-31 0000867840 us-gaap:AdditionalPaidInCapitalMember 2019-10-01 2019-12-31 0000867840 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0000867840 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0000867840 us-gaap:RetainedEarningsMember 2018-10-01 2018-12-31 0000867840 us-gaap:RetainedEarningsMember 2019-10-01 2019-12-31 0000867840 us-gaap:RetainedEarningsMember 2018-09-30 0000867840 us-gaap:RetainedEarningsMember 2019-09-30 0000867840 2018-10-01 2018-12-31 0000867840 2019-10-01 2019-12-31 0000867840 2018-09-30 0000867840 2019-09-30 0000867840 2020-01-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares 0.01 0.01 50000000 50000000 2072800 1462000 2072800 1462000 40000 60000 100000 44000 100000 786000 6000 36000 45000 478000 100000 70000 2072800 207800 1819500 0.27 0.48 0.5 0.55 0.7 0.73 0.85 0.9 1.25 1.3 1.42 1.5 0.95 1.2 0.87 0.27 0.48 0.5 0.55 0.7 0.73 0.85 0.9 1.2 1.25 1.3 0.27–$1.50 1.42 1.5 941830 887280 PRECISION OPTICS CORPORATION, INC. 0000867840 10-Q 2020-03-31 false --06-30 Yes Non-accelerated Filer Q3 2020 40000 60000 100000 44000 100000 786000 6000 36000 0 0 0 70000 1449800 207800 0.27 0.48 0.5 0.55 0.7 0.73 0.85 0.9 1.5 0.79 1.2 47500 P1Y3M15D P6Y P5Y2M19D P3Y11M15D P8Y4M6D P6Y6M21D P2Y9M3D P4Y2M8D P1Y11M1D P1Y2M30D P9Y2M12D P6Y9M25D P9Y5M12D P9Y11M15D 12071139 12991789 315000 P7Y18D 7686330 7348803 2374584 2413438 true false 346365 348870 33699 0 46714 7233 426778 356103 210000 75567 2891 11233 0 21346 2411 42988 480 Yes 001-10647 MA 13191789 246953 247701 12071139 12991789 -1103065 -505716 163828 -466130 -80483 -299285 -80483 -299285 -86110 -466130 -86110 75430 -125948 -550825 -125948 -550825 760000 1600000 14200 41000 12500 11742 11408 15190 61779 62822 139791 47750 0 0 0 0 45571 15190 300000 564036 3376891 2779279 2431548 101972 120382 45484186 47839004 -45022122 -45527838 120712 129918 48893172 49389419 -45636993 -46740058 118972 47797398 -45447355 2469015 128801 49314969 -46273928 3169842 102972 128687 45826170 49040377 -45321407 -45723103 607735 3445961 false 7493230 5847364 687664 687664 54087 86908 132000 383006 530782 3202605 3278054 3585611 3808836 168450 178640 668446 724680 2748715 2905516 6368473 4410010 180336 131279 2165107 1479077 7493230 5847364 -45636993 -46740058 48893172 49389419 120712 129918 0 75804 500000 500000 5027 38001 3611312 2454280 0 56196 1443341 0 533944 483781 1174263 1533342 9572 70436 -138 -1150 -683 -304 -1102927 -504566 -465447 -80179 3812002 1778731 1282466 536115 3111397 1430880 962591 414475 700605 347851 319875 121640 2709075 1274165 817019 455936 10197139 12038139 12071139 12991789 11897139 12880047 10297139 12868639 100000 100000 25000 100000 1000 1000 -1000 -1000 250 1000 44750 -1000 45000 75567 2891 342984 2891 342984 76505 75567 76505 10228 274706 10228 274706 7600 17400 25000 16000 1961000 1977000 29375 410 28965 125 117 8550 -117 8675 114 -114 10750 10750 8258 3592 23000 23000 8000 -84421 -954132 -50163 -85236 -139667 -598914 359079 -59721 -49057 68447 432919 -14222 -686030 29905 -45000 0 426778 356103 75449 23482 402738 2288426 632131 1352767 -1656295 950029 14300 2018459 8675 29375 25000 2000000 19375 6666 -1586174 -114298 110012 111766 32821 2532 1443341 0 0 912 -0.09 0.01 -0.04 0.01 -0.09 0.01 -0.04 0.01 857842 450192 310525 258928 294650 388506 474560 680598 119855 97650 334893 81684 41874 61928 108437 51252 65463 8324 116761 11280 54593 21748 11280 11280 6580 0 0 0 1734604 2167523 746729 772484 409019 743100 578856 651939 -0.09 -0.04 -0.04 -0.01 12898004 11294902 12982494 12020328 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 5%; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">1.</font></td> <td style="width: 95%; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</u></font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><u>Principles of Consolidation and Operations</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements include the accounts of Precision Optics Corporation,&#160;Inc. and its wholly owned subsidiaries (the &#8220;Company&#8221;). All significant intercompany accounts and transactions have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These consolidated financial statements have been prepared by the Company, without audit, and reflect normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the results of the third quarter and nine months of the Company&#8217;s fiscal year 2020. These consolidated financial statements do not include all disclosures associated with annual consolidated financial statements and, accordingly, should be read in conjunction with footnotes contained in the Company&#8217;s consolidated financial statements for the year ended June&#160;30, 2019, together with the Report of Independent Registered Public Accounting Firm filed under cover of the Company&#8217;s 2019 Annual Report on Form&#160;10-K, filed with the Securities and Exchange Commission on September 26, 2019.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><u>Use of Estimates</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of these consolidated financial statements requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><u>Reclassification</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain balance sheet items in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. This reclassification had no effect on the previously reported net loss.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><u>Income (Loss) Per Share</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic income (loss) per share is computed by dividing net income or net loss by the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share is computed by dividing net income or net loss by the weighted average number of shares of common stock outstanding during the period, plus the number of potentially dilutive securities outstanding during the period such as stock options and warrants. For the three and nine months ended March 31, 2020 and 2019, the effect of such securities was antidilutive and not included in the diluted calculation because of the net loss generated in these periods.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following is the calculation of loss per share for the three and nine months ended March 31, 2020 and 2019:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-left: 10pt; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months<br /> Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine Months<br /> Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 10pt; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt; width: 48%; text-align: left; padding-bottom: 2.5pt; text-indent: -10pt">Net Loss - Basic and Diluted</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</td><td style="width: 10%; border-bottom: Black 2.5pt double; text-align: right">(466,130</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</td><td style="width: 10%; border-bottom: Black 2.5pt double; text-align: right">(80,483</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</td><td style="width: 10%; border-bottom: Black 2.5pt double; text-align: right">(1,103,065</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</td><td style="width: 10%; border-bottom: Black 2.5pt double; text-align: right">(505,716</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt; text-indent: -10pt">Basic and Dilutive Weighted Average Shares Outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,982,494</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,020,328</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,898,004</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,294,902</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt; text-indent: -10pt">Loss Per Share - Basic and Diluted</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.04</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.01</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.09</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.04</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The number of shares issuable upon the exercise of outstanding stock options and warrants that were excluded from the computation as their effect was antidilutive was approximately 2,072,800 and 1,462,000 for the three and nine months ended March 31, 2020 and 2019, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><u>Income Taxes</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In assessing the likelihood of utilization of existing deferred tax assets, management has considered historical results of operations and the current operating environment. Based on this evaluation, a full valuation reserve has been provided for the deferred tax assets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><u>Goodwill and Patents</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Long-lived assets such as goodwill and patents are capitalized when acquired and reviewed for impairment whenever events or changes in circumstances indicate that the book value of the asset may not be recoverable. Impairment of the carrying value of long-lived assets such as goodwill and patents would be indicated if the best estimate of future undiscounted cash flows expected to be generated by the asset grouping is less than its carrying value. If an impairment is indicated, any loss is measured as the difference between estimated fair value and carrying value and is recognized in operating income or loss. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. No such impairments of goodwill or patents have been estimated by management as of March 31, 2020.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><u>Accounting Pronouncements Recently Adopted</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 1, 2019, the Company adopted ASU 2016-02, Topic 842 &#8211; Leases. Refer to Note 3 for further information.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 5%; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">3.</font></td> <td style="width: 95%; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>LEASE OBLIGATIONS</u></font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company entered into a five-year capital lease obligation in January 2016 for the acquisition of manufacturing equipment totaling $51,252. In January 2020 the Company entered into a five-year capital lease and a twelve-month operating lease for $47,750 and $65,463 respectively for the acquisition of manufacturing equipment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2016, FASB issued ASU 2016-02, &#8220;Leases&#8221; (Topic 842). ASU 2016-02 requires the recognition of lease asset and lease liabilities by lessees for those leases currently classified as operating leases with terms greater than twelve months and make certain changes to the accounting for lease expenses. The Company adopted this standard effective July 1, 2019 and has reflected its impact upon the El Paso, Texas facility operating lease entered into on July 1, 2019 in connection with the Ross Optical acquisition. The facility lease is a three-year operating lease obligation with total remaining minimum lease payments of $139,791 at March 31, 2020. Total rent expense including base rent and common area expenses were $15,190 and $45,571 during the three and nine months ended March 31, 2020, respectively. Included in the accompanying balance sheet at March 31, 2020 is a right-of-use asset of $132,000 and current and long-term right-of-use operating lease liabilities of $56,196 and $75,804, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At March 31, 2020, future minimum lease payments under the capital lease and operating lease obligations are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">Fiscal Year Ending June 30:</font></td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Capital Leases</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Operating Lease</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 67%"><font style="font: 10pt Times New Roman, Times, Serif">2020</font></td> <td style="width: 2%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">21,748</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">15,190</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><font style="font: 10pt Times New Roman, Times, Serif">2021</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">54,593</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">61,779</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td><font style="font: 10pt Times New Roman, Times, Serif">2022</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">11,280</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">62,822</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><font style="font: 10pt Times New Roman, Times, Serif">2023</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">11,280</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8211;</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td><font style="font: 10pt Times New Roman, Times, Serif">2024</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">11,280</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8211;</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><font style="font: 10pt Times New Roman, Times, Serif">2025</font></td> <td>&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,580</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8211;</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td><font style="font: 10pt Times New Roman, Times, Serif">Total Minimum Payments</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">116,761</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">139,791</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><font style="font: 10pt Times New Roman, Times, Serif">Less: amount representing interest</font></td> <td>&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8,324</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td><font style="font: 10pt Times New Roman, Times, Serif">Present value of minimum lease payments</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">108,437</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><font style="font: 10pt Times New Roman, Times, Serif">Less: current portion</font></td> <td>&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">70,436</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">38,001</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 5%; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">2.</font></td> <td style="width: 95%; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>INVENTORIES</u></font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventories are stated at the lower of cost (first-in, first-out) and net realizable value and consisted of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,<br /> 2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30,<br /> 2019</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Raw Materials</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">651,939</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">578,856</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Work-In-Progress</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">743,100</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">409,019</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Finished Goods</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">772,484</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">746,729</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total Inventories</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,167,523</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,734,604</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 5%"><font style="font: 10pt Times New Roman, Times, Serif">4.</font></td> <td style="width: 95%"><font style="font: 10pt Times New Roman, Times, Serif"><u>STOCK-BASED COMPENSATION</u></font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes stock-based compensation expense for the three and nine months ended March 31, 2020 and 2019:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months<br /> Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine Months<br /> Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 48%; text-align: left">Cost of Goods Sold</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">11,233</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">&#8211;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">33,699</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">&#8211;</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and Development</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">21,346</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,411</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">46,714</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">7,233</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Selling, General and Administrative</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">42,988</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">480</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">346,365</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">348,870</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Stock Based Compensation Expense</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">75,567</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,891</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">426,778</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">356,103</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No compensation has been capitalized because such amounts would have been immaterial.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following tables summarize stock option activity for the nine months ended March 31, 2020:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="10" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Options Outstanding</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Number of<br /> Shares</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted Average<br /> Exercise Price</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted Average<br /> Contractual Life</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 52%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Outstanding at June 30, 2019</b></font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,819,500</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 13%; text-align: right">&#160;&#160;&#160;<font style="font: 10pt Times New Roman, Times, Serif">0.87</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7.05 years</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">315,000</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(47,500</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><font style="font: 10pt Times New Roman, Times, Serif">Expired or Cancelled</font></td> <td>&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(14,200</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>Outstanding at March 31, 2020</b></font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,072,800</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.95</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6.82 years</font></td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Information related to the stock options outstanding as of March 31, 2020 is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Range of Exercise</b><br /> <b>Prices</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Number of</b><br /> <b>Shares</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted-</b><br /> <b>Average </b><br /> <b>Remaining</b><br /> <b>Contractual Life</b><br /> <b>(years)</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted-</b><br /> <b>Average </b><br /> <b>Exercise</b><br /> <b>Price</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Exercisable </b><br /> <b>Number of</b><br /> <b>Shares</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Exercisable</b><br /> <b>Weighted-</b><br /> <b>Average </b><br /> <b>Exercise</b><br /> <b>Price</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 14%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.27</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 14%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">40,000</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: center">&#160;</td> <td style="width: 13%; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.29</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 14%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.27</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 14%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">40,000</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 14%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.27</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.48</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">60,000</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">6.00</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.48</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">60,000</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.48</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.50</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">100,000</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">5.22</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.50</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">100,000</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.50</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.55</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">44,000</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">3.96</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.55</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">44,000</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.55</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.70</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">100,000</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">8.35</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.70</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">100,000</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.70</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.73</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">786,000</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">6.56</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.73</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">786,000</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.73</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.85</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,000</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2.76</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.85</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,000</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.85</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.90</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">36,000</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">4.19</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.90</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">36,000</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.90</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.20</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">207,800</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.92</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.20</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">207,800</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.20</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.25</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">45,000</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.25</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.25</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.30</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">478,000</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">9.20</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.30</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.42</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">100,000</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">9.45</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.42</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.50</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">70,000</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">9.96</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.50</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">70,000</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.50</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.27&#8211;$1.50</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,072,800</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">6.82</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.95</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,449,800</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.79</font></td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate intrinsic value of the Company&#8217;s &#8220;in-the-money&#8221; outstanding and exercisable options as of the three and nine months ended March 31, 2020 was $941,830 and $887,280, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><u>Common Stock Award</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 2, 2018, the Company awarded its Chief Executive Officer 300,000 shares of common stock for services performed through June 30, 2018. The fair market value of the 300,000 shares on the award date equal to $210,000 has been recorded as general and administrative stock-based compensation expense in the quarter ended September 30, 2018. As of March 31, 2020, all 300,000 shares have been issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 5%"><font style="font: 10pt Times New Roman, Times, Serif">5.</font></td> <td style="width: 95%"><font style="font: 10pt Times New Roman, Times, Serif"><u>REVENUE RECOGNITION</u></font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 1, 2018, the Company adopted ASU 2014-09 Revenue from Contracts with Customers (ASC 606) using the modified retrospective method for contracts that were not completed as of July 1, 2018, whereby revenues are recognized as the performance obligations to deliver products or services are satisfied and are recorded based on the amount of consideration the Company expects to receive in exchange for satisfying the performance obligations. Most of the Company&#8217;s products and services are marketed to medical device companies almost exclusively in the United States. Products and services are primarily transferred to customers at a point in time based upon when services are performed or product is shipped.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenues represent the amount of consideration the Company expects to receive from customers in exchange for transferring products and services. Other selling costs to obtain and fulfill contracts are expensed as incurred due to the short-term nature of a majority of its revenues. The Company extends terms of payment to its customers based on commercially reasonable terms for the markets of its customers, while also considering their credit quality. Shipping and handling costs charged to customers are included in revenues.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company disaggregates revenues by product and service types as it believes it best depicts how the nature, amount, timing and uncertainty of revenues and cash flows are affected by economic factors. Revenues are comprised of the following for the three and nine months ended March 31, 2020 and 2019:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months<br /> Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine Months<br /> Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 48%; text-align: left">Engineering Design Services</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">210,065</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">61,833</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,098,234</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">892,472</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Optical Components</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,479,322</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">250,405</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">4,428,409</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">774,429</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Medical Device Products and Assemblies</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">685,197</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,074,216</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,159,687</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,756,862</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total Revenues</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,374,584</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,386,454</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,686,330</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,423,763</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Contract Assets and Liabilities</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The nature of the Company&#8217;s products and services does not generally give rise to contract assets as it typically does not incur costs to fulfill a contract before a product or service is provided to a customer. The Company&#8217;s costs to obtain contracts are typically in the form of sales commissions paid to employees. The Company has elected to expense sales commissions associated with obtaining a contract as incurred as the amortization period is generally less than one year. These costs have been recorded in selling, general and administrative expenses. As of March 31, 2020, there were no contract assets recorded in the Company&#8217;s Consolidated Balance Sheets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s contract liabilities arise as a result of unearned revenue received from customers at inception of contracts or where the timing of billing for services precedes satisfaction of our performance obligations. The Company generally satisfies performance obligations within one year from the contract inception date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Contract liabilities, which were recorded as customer advances in the Company&#8217;s Consolidated Balance Sheets, and unearned revenue are comprised of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months<br /> Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine Months<br /> Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 48%">Contract liabilities, beginning of period</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">388,506</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">294,650</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">450,192</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">857,842</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Unearned revenue received from customers</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">41,874</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">61,928</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">334,893</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">81,684</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Revenue recognized</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(119,855</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(97,650</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(474,560</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(680,598</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Contract liabilities, end of period</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">310,525</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">258,928</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">310,525</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">258,928</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 5%"><font style="font: 10pt Times New Roman, Times, Serif">6.</font></td> <td style="width: 95%"><font style="font: 10pt Times New Roman, Times, Serif">BUSINESS ACQUISITION</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 1, 2019 the Company acquired the operating assets of Ross Optical Industries, Inc. of El Paso, Texas, a supplier of custom and catalogue optical components sourced through an extensive network of worldwide specialized vendors and sold for industrial, military and medical applications. The acquisition had an effective date of June 1, 2019. All of Ross&#8217; results of operations are included in our financial statements for the three- and nine-month periods ended March 31, 2020.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Consolidated unaudited actual and pro forma results of operations for the Company are presented below assuming that the acquisition of the Ross Optical division had occurred on July 1, 2018. Pro forma operating results include net adjustments resulting from the acquisition transaction.<b></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months<br /> Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine Months<br /> Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">(Actual)</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">(Pro Forma)</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">(Actual)</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">(Pro Forma)</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 48%">Revenues</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">2,374,584</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">2,413,438</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">7,686,330</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">7,348,803</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net income (loss)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(466,130</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">75,430</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(1,103,065</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">163,828</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Income (loss) per share</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Basic</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(0.04</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">0.01</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(0.09</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">0.01</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Fully diluted</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(0.04</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">0.01</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(0.09</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">0.01</td><td style="text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pro forma financial information is not necessarily indicative of the Company&#8217;s actual results of operations if the acquisition had been completed at the date indicated, nor is it necessarily an indication of future operating results. Amounts do not include any operating efficiencies or cost saving that the Company believes may become achievable over time.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 5%"><font style="font: 10pt Times New Roman, Times, Serif">8.</font></td> <td style="width: 95%"><font style="font: 10pt Times New Roman, Times, Serif">SUBSEQUENT EVENT</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 14, 2020, the Company entered into agreements with accredited investors for the sale and purchase of 200,000 shares of its common stock, $0.01 par value at a purchase price of $1.25 per share. The Company received $250,000 in gross proceeds from the offering. The Company entered into this stock offering transaction in order to enhance its financial condition given uncertainties surrounding the COVID-19 pandemic and its potential impact on domestic and international sources of supply as well as the financial condition of its customers and the status of existing and future sales orders from them. The agreements also provide for the investors to receive additional shares of our common stock in the event the Company closes a subsequent offering of its common stock at a purchase price lower than $1.25 per share before April 14, 2021. The additional shares each investor would receive would be equal to the difference between the number of shares that would have been received at the reduced purchase price and the number of shares received at the $1.25 purchase price. The Company intends to use the proceeds from this placement for general working capital purposes.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In conjunction with the placement, the Company also entered into a registration rights agreement with the investors, whereby it is obligated to file a registration statement with the Securities Exchange Commission on or before 120 calendar days after April 14, 2020 to register the resale by the investors of 200,000 shares of our common stock purchased in the placement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 6, 2020, the Company received loan proceeds in the amount of $808,962 under the Paycheck Protection Program, or PPP, from Bank of America. The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act, or CARES Act, provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The loans and accrued interest are forgivable after eight weeks as long as the Company uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and we maintain our payroll levels. The amount of loan forgiveness will be reduced if the Company terminates employees or reduces salaries during the eight-week period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unsecured loan, which is in the form of a note dated May 6, 2020, matures on May 6, 2022 and bears interest at a rate of 1% per annum, payable monthly commencing on December 6, 2020. The note may be prepaid at any time prior to maturity with no prepayment penalties. The Company intends to use the loan amount for eligible purposes, such as payroll expenses. While the Company currently believes that its use of the loan proceeds will meet the conditions for forgiveness of the loan, the Company cannot assure that it will be eligible for forgiveness, in whole or in part.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 5%"><font style="font: 10pt Times New Roman, Times, Serif">7.</font></td> <td style="width: 95%"><font style="font: 10pt Times New Roman, Times, Serif">COVID-19 PANDEMIC</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The world-wide COVID-19 pandemic that began during the quarter ended March 31, 2020 and the domestic and international impact of policy decisions being made in major countries around the world has had, and is expected to have, an adverse impact on the Company&#8217;s sources of supply, current and future orders from the Company&#8217;s customers, collection of amounts owed to it from its customers, the Company&#8217;s internal operating procedures, and the Company&#8217;s overall financial condition. While the Company and many of its medical device and defense contracting customers continue to operate as essential businesses, the Company has taken various actions to augment its operating and human resource policies and procedures to guard against the potential health hazards of COVID-19. These augmented procedures can have a negative impact on the Company&#8217;s operational efficiencies. The Company sources various components from overseas suppliers throughout Asia, including China. The Company has experienced supply disruptions and customer delays, which it believes were the result of the COVID-19 pandemic and related economic slow-down. Given the uncertainty surrounding the continuation of economic slow-downs domestically and abroad, the Company cannot predict with certainty at this time what the future impact of COVID-19 and resulting business and economic policies in the US and abroad will be on its upcoming quarterly fiscal operating results.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><u>Principles of Consolidation and Operations</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements include the accounts of Precision Optics Corporation,&#160;Inc. and its wholly owned subsidiaries (the &#8220;Company&#8221;). All significant intercompany accounts and transactions have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These consolidated financial statements have been prepared by the Company, without audit, and reflect normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the results of the third quarter and nine months of the Company&#8217;s fiscal year 2020. These consolidated financial statements do not include all disclosures associated with annual consolidated financial statements and, accordingly, should be read in conjunction with footnotes contained in the Company&#8217;s consolidated financial statements for the year ended June&#160;30, 2019, together with the Report of Independent Registered Public Accounting Firm filed under cover of the Company&#8217;s 2019 Annual Report on Form&#160;10-K, filed with the Securities and Exchange Commission on September 26, 2019.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><u>Use of Estimates</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of these consolidated financial statements requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><u>Reclassification</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain balance sheet items in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. This reclassification had no effect on the previously reported net loss.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><u>Income (Loss) Per Share</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic income (loss) per share is computed by dividing net income or net loss by the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share is computed by dividing net income or net loss by the weighted average number of shares of common stock outstanding during the period, plus the number of potentially dilutive securities outstanding during the period such as stock options and warrants. For the three and nine months ended March 31, 2020 and 2019, the effect of such securities was antidilutive and not included in the diluted calculation because of the net loss generated in these periods.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following is the calculation of loss per share for the three and nine months ended March 31, 2020 and 2019:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-left: 10pt; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months<br /> Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine Months<br /> Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 10pt; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt; width: 48%; text-align: left; padding-bottom: 2.5pt; text-indent: -10pt">Net Loss - Basic and Diluted</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</td><td style="width: 10%; border-bottom: Black 2.5pt double; text-align: right">(466,130</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</td><td style="width: 10%; border-bottom: Black 2.5pt double; text-align: right">(80,483</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</td><td style="width: 10%; border-bottom: Black 2.5pt double; text-align: right">(1,103,065</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</td><td style="width: 10%; border-bottom: Black 2.5pt double; text-align: right">(505,716</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt; text-indent: -10pt">Basic and Dilutive Weighted Average Shares Outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,982,494</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,020,328</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,898,004</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,294,902</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt; text-indent: -10pt">Loss Per Share - Basic and Diluted</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.04</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.01</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.09</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.04</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The number of shares issuable upon the exercise of outstanding stock options and warrants that were excluded from the computation as their effect was antidilutive was approximately 2,072,800 and 1,462,000 for the three and nine months ended March 31, 2020 and 2019, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><u>Income Taxes</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In assessing the likelihood of utilization of existing deferred tax assets, management has considered historical results of operations and the current operating environment. Based on this evaluation, a full valuation reserve has been provided for the deferred tax assets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><u>Goodwill and Patents</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Long-lived assets such as goodwill and patents are capitalized when acquired and reviewed for impairment whenever events or changes in circumstances indicate that the book value of the asset may not be recoverable. Impairment of the carrying value of long-lived assets such as goodwill and patents would be indicated if the best estimate of future undiscounted cash flows expected to be generated by the asset grouping is less than its carrying value. If an impairment is indicated, any loss is measured as the difference between estimated fair value and carrying value and is recognized in operating income or loss. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. No such impairments of goodwill or patents have been estimated by management as of March 31, 2020.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><u>Accounting Pronouncements Recently Adopted</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 1, 2019, the Company adopted ASU 2016-02, Topic 842 &#8211; Leases. Refer to Note 3 for further information.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following is the calculation of loss per share for the three and nine months ended March 31, 2020 and 2019:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-left: 10pt; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months<br /> Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine Months<br /> Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 10pt; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt; width: 48%; text-align: left; padding-bottom: 2.5pt; text-indent: -10pt">Net Loss - Basic and Diluted</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</td><td style="width: 10%; border-bottom: Black 2.5pt double; text-align: right">(466,130</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</td><td style="width: 10%; border-bottom: Black 2.5pt double; text-align: right">(80,483</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</td><td style="width: 10%; border-bottom: Black 2.5pt double; text-align: right">(1,103,065</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td> <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</td><td style="width: 10%; border-bottom: Black 2.5pt double; text-align: right">(505,716</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt; text-indent: -10pt">Basic and Dilutive Weighted Average Shares Outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,982,494</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,020,328</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,898,004</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,294,902</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt; text-indent: -10pt">Loss Per Share - Basic and Diluted</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.04</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.01</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.09</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.04</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventories are stated at the lower of cost (first-in, first-out) and net realizable value and consisted of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,<br /> 2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30,<br /> 2019</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Raw Materials</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">651,939</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">578,856</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Work-In-Progress</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">743,100</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">409,019</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Finished Goods</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">772,484</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">746,729</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total Inventories</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,167,523</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,734,604</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 5%; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">3.</font></td> <td style="width: 95%; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>LEASE OBLIGATIONS</u></font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company entered into a five-year capital lease obligation in January 2016 for the acquisition of manufacturing equipment totaling $51,252. In January 2020 the Company entered into a five-year capital lease and a twelve-month operating lease for $47,750 and $65,463 respectively for the acquisition of manufacturing equipment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2016, FASB issued ASU 2016-02, &#8220;Leases&#8221; (Topic 842). ASU 2016-02 requires the recognition of lease asset and lease liabilities by lessees for those leases currently classified as operating leases with terms greater than twelve months and make certain changes to the accounting for lease expenses. The Company adopted this standard effective July 1, 2019 and has reflected its impact upon the El Paso, Texas facility operating lease entered into on July 1, 2019 in connection with the Ross Optical acquisition. The facility lease is a three-year operating lease obligation with total remaining minimum lease payments of $139,791 at March 31, 2020. Total rent expense including base rent and common area expenses were $15,190 and $45,571 during the three and nine months ended March 31, 2020, respectively. Included in the accompanying balance sheet at March 31, 2020 is a right-of-use asset of $132,000 and current and long-term right-of-use operating lease liabilities of $56,196 and $75,804, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At March 31, 2020, future minimum lease payments under the capital lease and operating lease obligations are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">Fiscal Year Ending June 30:</font></td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Capital Leases</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Operating Lease</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 67%"><font style="font: 10pt Times New Roman, Times, Serif">2020</font></td> <td style="width: 2%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">21,748</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">15,190</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><font style="font: 10pt Times New Roman, Times, Serif">2021</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">54,593</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">61,779</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td><font style="font: 10pt Times New Roman, Times, Serif">2022</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">11,280</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">62,822</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><font style="font: 10pt Times New Roman, Times, Serif">2023</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">11,280</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8211;</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td><font style="font: 10pt Times New Roman, Times, Serif">2024</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">11,280</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8211;</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><font style="font: 10pt Times New Roman, Times, Serif">2025</font></td> <td>&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,580</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8211;</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td><font style="font: 10pt Times New Roman, Times, Serif">Total Minimum Payments</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">116,761</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">139,791</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><font style="font: 10pt Times New Roman, Times, Serif">Less: amount representing interest</font></td> <td>&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8,324</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td><font style="font: 10pt Times New Roman, Times, Serif">Present value of minimum lease payments</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">108,437</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><font style="font: 10pt Times New Roman, Times, Serif">Less: current portion</font></td> <td>&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">70,436</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">38,001</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes stock-based compensation expense for the three and nine months ended March 31, 2020 and 2019:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months<br /> Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine Months<br /> Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 48%; text-align: left">Cost of Goods Sold</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">11,233</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">&#8211;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">33,699</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">&#8211;</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and Development</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">21,346</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,411</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">46,714</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">7,233</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Selling, General and Administrative</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">42,988</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">480</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">346,365</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">348,870</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Stock Based Compensation Expense</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">75,567</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,891</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">426,778</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">356,103</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following tables summarize stock option activity for the nine months ended March 31, 2020:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="10" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Options Outstanding</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Number of<br /> Shares</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted Average<br /> Exercise Price</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted Average<br /> Contractual Life</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 52%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Outstanding at June 30, 2019</b></font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,819,500</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 13%; text-align: right">&#160;&#160;&#160;<font style="font: 10pt Times New Roman, Times, Serif">0.87</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7.05 years</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">315,000</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(47,500</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><font style="font: 10pt Times New Roman, Times, Serif">Expired or Cancelled</font></td> <td>&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(14,200</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>Outstanding at March 31, 2020</b></font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,072,800</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.95</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6.82 years</font></td> <td>&#160;</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Information related to the stock options outstanding as of March 31, 2020 is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Range of Exercise</b><br /> <b>Prices</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Number of</b><br /> <b>Shares</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted-</b><br /> <b>Average </b><br /> <b>Remaining</b><br /> <b>Contractual Life</b><br /> <b>(years)</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted-</b><br /> <b>Average </b><br /> <b>Exercise</b><br /> <b>Price</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Exercisable </b><br /> <b>Number of</b><br /> <b>Shares</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Exercisable</b><br /> <b>Weighted-</b><br /> <b>Average </b><br /> <b>Exercise</b><br /> <b>Price</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 14%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.27</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 14%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">40,000</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: center">&#160;</td> <td style="width: 13%; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.29</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 14%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.27</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 14%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">40,000</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 14%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.27</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.48</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">60,000</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">6.00</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.48</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">60,000</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.48</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.50</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">100,000</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">5.22</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.50</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">100,000</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.50</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.55</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">44,000</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">3.96</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.55</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">44,000</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.55</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.70</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">100,000</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">8.35</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.70</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">100,000</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.70</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.73</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">786,000</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">6.56</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.73</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">786,000</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.73</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.85</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,000</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2.76</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.85</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,000</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.85</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.90</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">36,000</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">4.19</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.90</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">36,000</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.90</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.20</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">207,800</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.92</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.20</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">207,800</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.20</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.25</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">45,000</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1.25</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.25</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.30</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">478,000</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">9.20</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.30</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.42</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">100,000</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">9.45</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.42</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.50</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">70,000</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">9.96</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.50</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1pt solid">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">70,000</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.50</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.27&#8211;$1.50</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,072,800</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">6.82</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.95</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,449,800</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.79</font></td> <td>&#160;</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenues are comprised of the following for the three and nine months ended March 31, 2020 and 2019:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months<br /> Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine Months<br /> Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 48%; text-align: left">Engineering Design Services</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">210,065</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">61,833</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,098,234</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">892,472</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Optical Components</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,479,322</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">250,405</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">4,428,409</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">774,429</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Medical Device Products and Assemblies</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">685,197</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,074,216</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,159,687</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,756,862</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total Revenues</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,374,584</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,386,454</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,686,330</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,423,763</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Contract liabilities, which were recorded as customer advances in the Company&#8217;s Consolidated Balance Sheets, and unearned revenue are comprised of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months<br /> Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine Months<br /> Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 48%">Contract liabilities, beginning of period</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">388,506</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">294,650</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">450,192</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">857,842</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Unearned revenue received from customers</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">41,874</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">61,928</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">334,893</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">81,684</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Revenue recognized</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(119,855</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(97,650</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(474,560</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(680,598</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Contract liabilities, end of period</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">310,525</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">258,928</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">310,525</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">258,928</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pro forma operating results include net adjustments resulting from the acquisition transaction.<b></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months<br /> Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine Months<br /> Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">(Actual)</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">(Pro Forma)</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">(Actual)</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">(Pro Forma)</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 48%">Revenues</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">2,374,584</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">2,413,438</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">7,686,330</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">7,348,803</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net income (loss)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(466,130</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">75,430</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(1,103,065</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">163,828</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Income (loss) per share</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Basic</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(0.04</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">0.01</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(0.09</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">0.01</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Fully diluted</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(0.04</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">0.01</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(0.09</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">0.01</td><td style="text-align: left">&#160;</td></tr></table> 7686330 4423763 1098234 892472 4428409 774429 2159687 2756862 2374584 1386454 210065 61833 1479322 250405 685197 1074216 4977255 3149598 1557565 930518 0 4250 113213 0 EX-101.SCH 6 peye-20200331.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - 2. INVENTORIES link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - 3. LEASE OBLIGATIONS link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - 4. STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - 5. REVENUE RECOGNITION link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - 6. BUSINESS ACQUISITION link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - 7. COVID-19 PANDEMIC link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - 8. SUBSEQENT EVENT link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - 2. INVENTORIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - 3. LEASE OBLIGATIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - 4. STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - 5. REVENUE RECOGNITION (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - 6. BUSINESS ACQUISITION (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Loss per share) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - 2. INVENTORIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - 3. LEASE OBLIGATIONS (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - 3. LEASE OBLIGATIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - 4. STOCK-BASED COMPENSATION (Details - Stock based compensation) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - 4. STOCK-BASED COMPENSATION (Details - Option activity) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - 4. STOCK-BASED COMPENSATION (Details - Options by exercise price) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - 4. STOCK-BASED COMPENSATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - 5. REVENUE RECOGNITION (Details - Revenues) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - 5. REVENUE RECOGNITION (Details - Contract liabilities) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - 6. BUSINESS ACQUISITION (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 peye-20200331_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 peye-20200331_def.xml XBRL DEFINITION FILE EX-101.LAB 9 peye-20200331_lab.xml XBRL LABEL FILE Exercise Price Range [Axis] Option 1 [Member] Option 2 [Member] Option 3 [Member] Option 4 [Member] Option 5 [Member] Option 6 [Member] Option 7 [Member] Option 8 [Member] Option 9 [Member] Option 10 [Member] Income Statement Location [Axis] Selling, General and Administrative Expenses [Member] Cost of Goods Sold [Member] Research and Development Expenses [Member] Option 11 [Member] Award Type [Axis] Stock Options [Member] Option 12 [Member] Option 13 [Member] Product and Service [Axis] Engineering Design Services [Member] Optical Components [Member] Medical Device Products and Assemblies [Member] Equity Components [Axis] Common Stock [Member] Additional Paid-In Capital Retained Earnings / Accumulated Deficit Scenario [Axis] Pro Froma Related Party [Axis] Chief Executive Officer [Member] Accumulated Deficit Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Entity Small Business Entity Emerging Growth Entity Interactive data current Entity File number Entity Incorporation state code Entity shell company Statement of Financial Position [Abstract] ASSETS Current Assets: Cash and cash equivalents Accounts receivable (net of allowance for doubtful accounts of $247,701 and $246,953 at March 31, 2020 and June 30, 2019, respectively) Inventories Prepaid expenses Total current assets Fixed Assets: Machinery and equipment Leasehold improvements Furniture and fixtures Total Less: Accumulated depreciation and amortization Net Fixed Assets Operating lease right-to-use asset Patents, net Goodwill TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Current portion of capital lease obligation Accounts payable Customer advances Accrued compensation and other Amount due for business acquisition Operating lease liability Total Current Liabilities Capital lease obligation, net of current portion Acquisition earn out liability Operating lease liability Stockholders' Equity: Common stock, $0.01 par value: 50,000,000 shares authorized; issued and outstanding - 12,991,789 shares at March 31, 2020 and 12,071,139 shares at June 30, 2019 Additional paid-in capital Accumulated deficit Total stockholders' equity TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Allowance for doubtful accounts STOCKHOLDERS' EQUITY Common Stock par value Common Stock shares authorized Common Stock shares issued Common Stock shares outstanding Income Statement [Abstract] Revenues Cost of goods sold Gross profit Research and development expenses, net Selling, general and administrative expenses Total operating expenses Operating loss Interest Income (expense) Net loss Loss Per Share: Basic and diluted Weighted Average Common Shares Outstanding: Basic and diluted Statement [Table] Statement [Line Items] Beginning balance, shares Beginning balance, value Issuance of stock, private placement, shares Issuance of stock, private placement, value Exercise of stock options, shares Exercise of stock options, value Issuance of common stock for services, shares Issuance of common stock for services, value Adjust common stock issuance costs to actual Stock based compensation Net loss Ending balance, shares Ending balance, value Statement of Stockholders' Equity [Abstract] Exercise of stock options, net shares withheld Proceeds private placement stock, net of issuance costs Statement of Cash Flows [Abstract] Cash Flows from Operating Activities: Adjustments to Reconcile Net Loss to Net Cash Used In Operating Activities - Depreciation and amortization Stock-based compensation expense Non-cash consulting expense Changes in operating assets and liabilities Accounts receivable, net Inventories, net Prepaid expenses Accounts payable Customer advances Accrued compensation and other Net cash used in operating activities Cash Flows from Investing Activities: Cash paid for business acquisition Additional patent costs Purchases of property and equipment Net cash used in investing activities Cash Flows from Financing Activities: Payment of capital lease obligation Gross proceeds from private placement of common stock Gross proceeds from exercise of stock options Private placement expense paid Net cash provided from financing activities Net increase (decrease) in cash and cash equivalents Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Cash paid for income taxes Supplemental disclosure of non-cash financing and investing activities: Offering Costs Included in Accrued Liabilities Acquisition of Manufacturing Equipment Under Capital Lease Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Inventory Disclosure [Abstract] INVENTORIES Debt Disclosure [Abstract] LEASE OBLIGATIONS Share-based Payment Arrangement [Abstract] STOCK-BASED COMPENSATION Revenue from Contract with Customer [Abstract] REVENUE RECOGNITION Business Combinations [Abstract] BUSINESS ACQUISITION Covid-19 Pandemic COVID-19 PANDEMIC Subsequent Events [Abstract] SUBSEQUENT EVENT Principles of Consolidation and Operations Use of Estimates Reclassification Income (Loss) per Share Income Taxes Accounting Pronouncements Recently Adopted Goodwill and Patents Income (Loss) per Share Schedule of inventory Future minimum lease payments Schedule of stock-based compensation expense Stock option activity Stock options outstanding by exercise price range Disaggregation of revenues Contract Liabilities Pro forma operating results Net Loss - Basic and Diluted Basic and Diluted Weighted Average Shares Outstanding Loss Per Share - Basic and Diluted Outstanding stock options and warrants that were excluded from the computation as their effect was antidilutive Goodwill impairment Raw materials Work-in-progress Finished goods Total inventories Capital lease future minimum payments 2020 2021 2022 2023 2024 2025 Total minimum payments Less: amount representing interest Present value of minimum lease payments Less: current portion Capital lease obligation, noncurrent Operating lease future minimum payments 2020 2021 2022 2023 2024 2025 Total minimum payments Capital lease obligation Operating lease obligation Operating lease expense Right of use operating lease Right of use operating lease current Right of use operating lease noncurrent Stock based compensation expense Number of Shares Options outstanding, beginning Options granted Options expired or cancelled Options exercised Options outstanding, ending Weighted Average Exercise Price Weighted average exercise price, beginning price Weighted average exercise price, cancellations Weighted average exercise price, ending price Weighted Average Contractual Life Weighted Average Contractual Life, beginning Weighted Average Contractual Life, ending Range of exercise prices Number of shares outstanding Weighted average contractual life Weighted average exercise price Exercisable number of shares Exercisable weighted average exercise price Counterparty Name [Axis] Aggregate intrinsic value of "in the money" outstanding Aggregate intrinsic value of "in the money" exercisable Stock awarded for services, shares Share based compensation expense Contract liabilities, beginning balance Unearned revenue received from customers Revenue recognized in current period Contract liabilities, ending balance Revenues Net income (loss) Income (loss) per share Basic Fully Diluted Range of exercise prices Exercise of stock options, net shares withheld Option 10 member Custom Element. Option 1 member Option 2 member Option 3 member Option 4 member Option 5 member Option 6 member Option 7 member Option 8 member Option 9 member Proceeds private placement stock, net of issuance costs Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Offering Costs Included in Accrued Liabilities Disclosure for COVID-19 [Text Block] Assets, Current Property, Plant and Equipment, Gross Property, Plant and Equipment, Net Assets Liabilities, Current Stockholders' Equity Attributable to Parent Liabilities and Equity Gross Profit Operating Expenses Operating Income (Loss) Shares, Outstanding Other Noncash Income (Expense) Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Prepaid Expense Increase (Decrease) in Accounts Payable Increase (Decrease) in Contract with Customer, Liability Increase (Decrease) in Accrued Liabilities Net Cash Provided by (Used in) Operating Activities Payments to Acquire Businesses, Gross Payments to Acquire Intangible Assets Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Repayments of Debt and Lease Obligation Payments of Stock Issuance Costs Net Cash Provided by (Used in) Financing Activities Cash and Cash Equivalents, Period Increase (Decrease) Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block] Capital Leases, Future Minimum Payments Due Operating Leases, Future Minimum Payments, Remainder of Fiscal Year Operating Leases, Future Minimum Payments, Due in Two Years Operating Leases, Future Minimum Payments, Due in Three Years Operating Leases, Future Minimum Payments, Due in Four Years Operating Leases, Future Minimum Payments, Due in Five Years Operating Leases, Future Minimum Payments, Due Thereafter Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Contract with Customer, Liability, Revenue Recognized Revenues [Default Label] EX-101.PRE 10 peye-20200331_pre.xml XBRL PRESENTATION FILE XML 11 R21.htm IDEA: XBRL DOCUMENT v3.20.1
5. REVENUE RECOGNITION (Tables)
9 Months Ended
Mar. 31, 2020
Revenue from Contract with Customer [Abstract]  
Disaggregation of revenues

Revenues are comprised of the following for the three and nine months ended March 31, 2020 and 2019:

 

   Three Months
Ended March 31,
   Nine Months
Ended March 31,
 
   2020   2019   2020   2019 
Engineering Design Services  $210,065   $61,833   $1,098,234   $892,472 
Optical Components   1,479,322    250,405    4,428,409    774,429 
Medical Device Products and Assemblies   685,197    1,074,216    2,159,687    2,756,862 
Total Revenues  $2,374,584   $1,386,454   $7,686,330   $4,423,763 
Contract Liabilities

Contract liabilities, which were recorded as customer advances in the Company’s Consolidated Balance Sheets, and unearned revenue are comprised of the following:

 

   Three Months
Ended March 31,
   Nine Months
Ended March 31,
 
   2020   2019   2020   2019 
Contract liabilities, beginning of period  $388,506   $294,650   $450,192   $857,842 
Unearned revenue received from customers   41,874    61,928    334,893    81,684 
Revenue recognized   (119,855)   (97,650)   (474,560)   (680,598)
Contract liabilities, end of period  $310,525   $258,928   $310,525   $258,928 
XML 12 R25.htm IDEA: XBRL DOCUMENT v3.20.1
2. INVENTORIES (Details) - USD ($)
Mar. 31, 2020
Jun. 30, 2019
Inventory Disclosure [Abstract]    
Raw materials $ 651,939 $ 578,856
Work-in-progress 743,100 409,019
Finished goods 772,484 746,729
Total inventories $ 2,167,523 $ 1,734,604
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.20.1
CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($)
Mar. 31, 2020
Jun. 30, 2019
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts $ 247,701 $ 246,953
STOCKHOLDERS' EQUITY    
Common Stock par value $ 0.01 $ 0.01
Common Stock shares authorized 50,000,000 50,000,000
Common Stock shares issued 12,991,789 12,071,139
Common Stock shares outstanding 12,991,789 12,071,139
XML 14 R29.htm IDEA: XBRL DOCUMENT v3.20.1
4. STOCK-BASED COMPENSATION (Details - Option activity) - Stock Options [Member]
9 Months Ended
Mar. 31, 2020
$ / shares
shares
Number of Shares  
Options outstanding, beginning 1,819,500
Options granted 315,000
Options expired or cancelled (47,500)
Options exercised (14,200)
Options outstanding, ending 2,072,800
Weighted Average Exercise Price  
Weighted average exercise price, beginning price | $ / shares $ 0.87
Weighted average exercise price, ending price | $ / shares $ 0.95
Weighted Average Contractual Life  
Weighted Average Contractual Life, beginning 7 years 18 days
Weighted Average Contractual Life, ending 6 years 9 months 25 days
XML 15 R7.htm IDEA: XBRL DOCUMENT v3.20.1
CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
9 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Cash Flows from Operating Activities:    
Net loss $ (1,103,065) $ (505,716)
Adjustments to Reconcile Net Loss to Net Cash Used In Operating Activities -    
Depreciation and amortization 75,449 23,482
Stock-based compensation expense 426,778 356,103
Non-cash consulting expense 45,000 0
Changes in operating assets and liabilities    
Accounts receivable, net 686,030 (29,905)
Inventories, net (432,919) 14,222
Prepaid expenses 49,057 (68,447)
Accounts payable 359,079 (59,721)
Customer advances (139,667) (598,914)
Accrued compensation and other (50,163) (85,236)
Net cash used in operating activities (84,421) (954,132)
Cash Flows from Investing Activities:    
Cash paid for business acquisition (1,443,341) 0
Additional patent costs (32,821) (2,532)
Purchases of property and equipment (110,012) (111,766)
Net cash used in investing activities (1,586,174) (114,298)
Cash Flows from Financing Activities:    
Payment of capital lease obligation (19,375) (6,666)
Gross proceeds from private placement of common stock 25,000 2,000,000
Gross proceeds from exercise of stock options 8,675 29,375
Private placement expense paid 0 (4,250)
Net cash provided from financing activities 14,300 2,018,459
Net increase (decrease) in cash and cash equivalents (1,656,295) 950,029
Cash and cash equivalents, beginning of period 2,288,426 402,738
Cash and cash equivalents, end of period 632,131 1,352,767
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:    
Cash paid for income taxes 0 912
Supplemental disclosure of non-cash financing and investing activities:    
Offering Costs Included in Accrued Liabilities 23,000 8,000
Acquisition of Manufacturing Equipment Under Capital Lease $ 113,213 $ 0
XML 16 R34.htm IDEA: XBRL DOCUMENT v3.20.1
6. BUSINESS ACQUISITION (Details) - USD ($)
3 Months Ended 9 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Mar. 31, 2020
Mar. 31, 2019
Revenues $ 2,374,584           $ 7,686,330  
Net income (loss) $ (466,130) $ (550,825) $ (86,110) $ (80,483) $ (125,948) $ (299,285) $ (1,103,065) $ (505,716)
Income (loss) per share                
Basic $ (0.04)           $ (0.09)  
Fully Diluted $ (0.04)           $ (0.09)  
Pro Froma                
Revenues       2,413,438       7,348,803
Net income (loss)       $ 75,430       $ 163,828
Income (loss) per share                
Basic       $ 0.01       $ 0.01
Fully Diluted       $ 0.01       $ 0.01
XML 17 R30.htm IDEA: XBRL DOCUMENT v3.20.1
4. STOCK-BASED COMPENSATION (Details - Options by exercise price) - $ / shares
9 Months Ended
Mar. 31, 2020
Jun. 30, 2019
Stock Options [Member]    
Range of exercise prices 0.27–$1.50  
Number of shares outstanding 2,072,800 1,819,500
Weighted average contractual life 6 years 9 months 25 days  
Weighted average exercise price $ 0.95 $ 0.87
Exercisable number of shares 1,449,800  
Exercisable weighted average exercise price $ 0.79  
Option 1 [Member]    
Range of exercise prices 0.27  
Number of shares outstanding 40,000  
Weighted average contractual life 1 year 3 months 15 days  
Weighted average exercise price $ 0.27  
Exercisable number of shares 40,000  
Exercisable weighted average exercise price $ 0.27  
Option 2 [Member]    
Range of exercise prices 0.48  
Number of shares outstanding 60,000  
Weighted average contractual life 6 years  
Weighted average exercise price $ 0.48  
Exercisable number of shares 60,000  
Exercisable weighted average exercise price $ 0.48  
Option 3 [Member]    
Range of exercise prices 0.5  
Number of shares outstanding 100,000  
Weighted average contractual life 5 years 2 months 19 days  
Weighted average exercise price $ 0.5  
Exercisable number of shares 100,000  
Exercisable weighted average exercise price $ 0.5  
Option 4 [Member]    
Range of exercise prices 0.55  
Number of shares outstanding 44,000  
Weighted average contractual life 3 years 11 months 15 days  
Weighted average exercise price $ 0.55  
Exercisable number of shares 44,000  
Exercisable weighted average exercise price $ 0.55  
Option 5 [Member]    
Range of exercise prices 0.7  
Number of shares outstanding 100,000  
Weighted average contractual life 8 years 4 months 6 days  
Weighted average exercise price $ 0.7  
Exercisable number of shares 100,000  
Exercisable weighted average exercise price $ 0.7  
Option 6 [Member]    
Range of exercise prices 0.73  
Number of shares outstanding 786,000  
Weighted average contractual life 6 years 6 months 21 days  
Weighted average exercise price $ 0.73  
Exercisable number of shares 786,000  
Exercisable weighted average exercise price $ 0.73  
Option 7 [Member]    
Range of exercise prices 0.85  
Number of shares outstanding 6,000  
Weighted average contractual life 2 years 9 months 3 days  
Weighted average exercise price $ 0.85  
Exercisable number of shares 6,000  
Exercisable weighted average exercise price $ 0.85  
Option 8 [Member]    
Range of exercise prices 0.9  
Number of shares outstanding 36,000  
Weighted average contractual life 4 years 2 months 8 days  
Weighted average exercise price $ 0.9  
Exercisable number of shares 36,000  
Exercisable weighted average exercise price $ 0.9  
Option 9 [Member]    
Range of exercise prices 1.2  
Number of shares outstanding 207,800  
Weighted average contractual life 1 year 11 months 1 day  
Weighted average exercise price $ 1.2  
Exercisable number of shares 207,800  
Exercisable weighted average exercise price $ 1.2  
Option 10 [Member]    
Range of exercise prices 1.25  
Number of shares outstanding 45,000  
Weighted average contractual life 1 year 2 months 30 days  
Weighted average exercise price $ 1.25  
Exercisable number of shares 0  
Exercisable weighted average exercise price  
Option 11 [Member]    
Range of exercise prices 1.3  
Number of shares outstanding 478,000  
Weighted average contractual life 9 years 2 months 12 days  
Weighted average exercise price $ 1.3  
Exercisable number of shares 0  
Exercisable weighted average exercise price  
Option 12 [Member]    
Range of exercise prices 1.42  
Number of shares outstanding 100,000  
Weighted average contractual life 9 years 5 months 12 days  
Weighted average exercise price $ 1.42  
Exercisable number of shares 0  
Exercisable weighted average exercise price  
Option 13 [Member]    
Range of exercise prices 1.5  
Number of shares outstanding 70,000  
Weighted average contractual life 9 years 11 months 15 days  
Weighted average exercise price $ 1.5  
Exercisable number of shares 70,000  
Exercisable weighted average exercise price $ 1.5  
XML 18 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 19 R13.htm IDEA: XBRL DOCUMENT v3.20.1
6. BUSINESS ACQUISITION
9 Months Ended
Mar. 31, 2020
Business Combinations [Abstract]  
BUSINESS ACQUISITION

6. BUSINESS ACQUISITION

 

On July 1, 2019 the Company acquired the operating assets of Ross Optical Industries, Inc. of El Paso, Texas, a supplier of custom and catalogue optical components sourced through an extensive network of worldwide specialized vendors and sold for industrial, military and medical applications. The acquisition had an effective date of June 1, 2019. All of Ross’ results of operations are included in our financial statements for the three- and nine-month periods ended March 31, 2020.

  

Consolidated unaudited actual and pro forma results of operations for the Company are presented below assuming that the acquisition of the Ross Optical division had occurred on July 1, 2018. Pro forma operating results include net adjustments resulting from the acquisition transaction.

 

   Three Months
Ended March 31,
   Nine Months
Ended March 31,
 
   2020   2019   2020   2019 
   (Actual)   (Pro Forma)   (Actual)   (Pro Forma) 
Revenues  $2,374,584   $2,413,438   $7,686,330   $7,348,803 
Net income (loss)   (466,130)   75,430    (1,103,065)   163,828 
Income (loss) per share                    
Basic  $(0.04)  $0.01   $(0.09)  $0.01 
Fully diluted  $(0.04)  $0.01   $(0.09)  $0.01 

 

Pro forma financial information is not necessarily indicative of the Company’s actual results of operations if the acquisition had been completed at the date indicated, nor is it necessarily an indication of future operating results. Amounts do not include any operating efficiencies or cost saving that the Company believes may become achievable over time.

XML 20 R17.htm IDEA: XBRL DOCUMENT v3.20.1
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
9 Months Ended
Mar. 31, 2020
Accounting Policies [Abstract]  
Income (Loss) per Share

The following is the calculation of loss per share for the three and nine months ended March 31, 2020 and 2019:

 

   Three Months
Ended March 31,
   Nine Months
Ended March 31,
 
   2020   2019   2020   2019 
Net Loss - Basic and Diluted  $(466,130)  $(80,483)  $(1,103,065)  $(505,716)
                     
Basic and Dilutive Weighted Average Shares Outstanding   12,982,494    12,020,328    12,898,004    11,294,902 
                     
Loss Per Share - Basic and Diluted  $(0.04)  $(0.01)  $(0.09)  $(0.04)
XML 21 R31.htm IDEA: XBRL DOCUMENT v3.20.1
4. STOCK-BASED COMPENSATION (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Aug. 02, 2018
Mar. 31, 2020
Mar. 31, 2019
Sep. 30, 2018
Mar. 31, 2020
Mar. 31, 2019
Aggregate intrinsic value of "in the money" outstanding   $ 941,830     $ 941,830  
Aggregate intrinsic value of "in the money" exercisable   887,280     887,280  
Share based compensation expense   $ 75,567 $ 2,891   $ 426,778 $ 356,103
Common Stock [Member] | Chief Executive Officer [Member]            
Stock awarded for services, shares 300,000          
Share based compensation expense       $ 210,000    
ZIP 22 0001683168-20-001561-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001683168-20-001561-xbrl.zip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end XML 23 R12.htm IDEA: XBRL DOCUMENT v3.20.1
5. REVENUE RECOGNITION
9 Months Ended
Mar. 31, 2020
Revenue from Contract with Customer [Abstract]  
REVENUE RECOGNITION

5. REVENUE RECOGNITION

 

On July 1, 2018, the Company adopted ASU 2014-09 Revenue from Contracts with Customers (ASC 606) using the modified retrospective method for contracts that were not completed as of July 1, 2018, whereby revenues are recognized as the performance obligations to deliver products or services are satisfied and are recorded based on the amount of consideration the Company expects to receive in exchange for satisfying the performance obligations. Most of the Company’s products and services are marketed to medical device companies almost exclusively in the United States. Products and services are primarily transferred to customers at a point in time based upon when services are performed or product is shipped.

 

Revenues represent the amount of consideration the Company expects to receive from customers in exchange for transferring products and services. Other selling costs to obtain and fulfill contracts are expensed as incurred due to the short-term nature of a majority of its revenues. The Company extends terms of payment to its customers based on commercially reasonable terms for the markets of its customers, while also considering their credit quality. Shipping and handling costs charged to customers are included in revenues.

 

The Company disaggregates revenues by product and service types as it believes it best depicts how the nature, amount, timing and uncertainty of revenues and cash flows are affected by economic factors. Revenues are comprised of the following for the three and nine months ended March 31, 2020 and 2019:

 

   Three Months
Ended March 31,
   Nine Months
Ended March 31,
 
   2020   2019   2020   2019 
Engineering Design Services  $210,065   $61,833   $1,098,234   $892,472 
Optical Components   1,479,322    250,405    4,428,409    774,429 
Medical Device Products and Assemblies   685,197    1,074,216    2,159,687    2,756,862 
Total Revenues  $2,374,584   $1,386,454   $7,686,330   $4,423,763 

 

Contract Assets and Liabilities

 

The nature of the Company’s products and services does not generally give rise to contract assets as it typically does not incur costs to fulfill a contract before a product or service is provided to a customer. The Company’s costs to obtain contracts are typically in the form of sales commissions paid to employees. The Company has elected to expense sales commissions associated with obtaining a contract as incurred as the amortization period is generally less than one year. These costs have been recorded in selling, general and administrative expenses. As of March 31, 2020, there were no contract assets recorded in the Company’s Consolidated Balance Sheets.

 

The Company’s contract liabilities arise as a result of unearned revenue received from customers at inception of contracts or where the timing of billing for services precedes satisfaction of our performance obligations. The Company generally satisfies performance obligations within one year from the contract inception date.

 

Contract liabilities, which were recorded as customer advances in the Company’s Consolidated Balance Sheets, and unearned revenue are comprised of the following:

 

   Three Months
Ended March 31,
   Nine Months
Ended March 31,
 
   2020   2019   2020   2019 
Contract liabilities, beginning of period  $388,506   $294,650   $450,192   $857,842 
Unearned revenue received from customers   41,874    61,928    334,893    81,684 
Revenue recognized   (119,855)   (97,650)   (474,560)   (680,598)
Contract liabilities, end of period  $310,525   $258,928   $310,525   $258,928 

EXCEL 24 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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htm IDEA: XBRL DOCUMENT v3.20.1
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
9 Months Ended
Mar. 31, 2020
Accounting Policies [Abstract]  
Principles of Consolidation and Operations

Principles of Consolidation and Operations

 

The accompanying consolidated financial statements include the accounts of Precision Optics Corporation, Inc. and its wholly owned subsidiaries (the “Company”). All significant intercompany accounts and transactions have been eliminated in consolidation.

 

These consolidated financial statements have been prepared by the Company, without audit, and reflect normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the results of the third quarter and nine months of the Company’s fiscal year 2020. These consolidated financial statements do not include all disclosures associated with annual consolidated financial statements and, accordingly, should be read in conjunction with footnotes contained in the Company’s consolidated financial statements for the year ended June 30, 2019, together with the Report of Independent Registered Public Accounting Firm filed under cover of the Company’s 2019 Annual Report on Form 10-K, filed with the Securities and Exchange Commission on September 26, 2019.

Use of Estimates

Use of Estimates

 

The preparation of these consolidated financial statements requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Reclassification

Reclassification

 

Certain balance sheet items in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. This reclassification had no effect on the previously reported net loss.

Income (Loss) per Share

Income (Loss) Per Share

 

Basic income (loss) per share is computed by dividing net income or net loss by the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share is computed by dividing net income or net loss by the weighted average number of shares of common stock outstanding during the period, plus the number of potentially dilutive securities outstanding during the period such as stock options and warrants. For the three and nine months ended March 31, 2020 and 2019, the effect of such securities was antidilutive and not included in the diluted calculation because of the net loss generated in these periods.

 

The following is the calculation of loss per share for the three and nine months ended March 31, 2020 and 2019:

 

   Three Months
Ended March 31,
   Nine Months
Ended March 31,
 
   2020   2019   2020   2019 
Net Loss - Basic and Diluted  $(466,130)  $(80,483)  $(1,103,065)  $(505,716)
                     
Basic and Dilutive Weighted Average Shares Outstanding   12,982,494    12,020,328    12,898,004    11,294,902 
                     
Loss Per Share - Basic and Diluted  $(0.04)  $(0.01)  $(0.09)  $(0.04)

 

The number of shares issuable upon the exercise of outstanding stock options and warrants that were excluded from the computation as their effect was antidilutive was approximately 2,072,800 and 1,462,000 for the three and nine months ended March 31, 2020 and 2019, respectively.

Income Taxes

Income Taxes

 

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

 

In assessing the likelihood of utilization of existing deferred tax assets, management has considered historical results of operations and the current operating environment. Based on this evaluation, a full valuation reserve has been provided for the deferred tax assets.

Accounting Pronouncements Recently Adopted

Accounting Pronouncements Recently Adopted

 

On July 1, 2019, the Company adopted ASU 2016-02, Topic 842 – Leases. Refer to Note 3 for further information.

Goodwill and Patents

Goodwill and Patents

 

Long-lived assets such as goodwill and patents are capitalized when acquired and reviewed for impairment whenever events or changes in circumstances indicate that the book value of the asset may not be recoverable. Impairment of the carrying value of long-lived assets such as goodwill and patents would be indicated if the best estimate of future undiscounted cash flows expected to be generated by the asset grouping is less than its carrying value. If an impairment is indicated, any loss is measured as the difference between estimated fair value and carrying value and is recognized in operating income or loss. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. No such impairments of goodwill or patents have been estimated by management as of March 31, 2020.

XML 26 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 118 242 1 false 26 0 false 3 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://poci.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) Sheet http://poci.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Sheet http://poci.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Sheet http://poci.com/role/ConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) Sheet http://poci.com/role/ConsolidatedStatementsOfStockholdersEquity CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) Sheet http://poci.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) Statements 6 false false R7.htm 00000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://poci.com/role/ConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 7 false false R8.htm 00000008 - Disclosure - 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://poci.com/role/SummaryOfSignificantAccountingPolicies 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 00000009 - Disclosure - 2. INVENTORIES Sheet http://poci.com/role/Inventories 2. INVENTORIES Notes 9 false false R10.htm 00000010 - Disclosure - 3. LEASE OBLIGATIONS Sheet http://poci.com/role/LeaseObligations 3. LEASE OBLIGATIONS Notes 10 false false R11.htm 00000011 - Disclosure - 4. STOCK-BASED COMPENSATION Sheet http://poci.com/role/Stock-basedCompensation 4. STOCK-BASED COMPENSATION Notes 11 false false R12.htm 00000012 - Disclosure - 5. REVENUE RECOGNITION Sheet http://poci.com/role/RevenueRecognition 5. REVENUE RECOGNITION Notes 12 false false R13.htm 00000013 - Disclosure - 6. BUSINESS ACQUISITION Sheet http://poci.com/role/BusinessAcquisition 6. BUSINESS ACQUISITION Notes 13 false false R14.htm 00000014 - Disclosure - 7. COVID-19 PANDEMIC Sheet http://poci.com/role/Covid-19Pandemic 7. COVID-19 PANDEMIC Notes 14 false false R15.htm 00000015 - Disclosure - 8. SUBSEQENT EVENT Sheet http://poci.com/role/SubseqentEvent 8. SUBSEQENT EVENT Notes 15 false false R16.htm 00000016 - Disclosure - 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://poci.com/role/SummaryOfSignificantAccountingPoliciesPolicies 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 16 false false R17.htm 00000017 - Disclosure - 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://poci.com/role/SummaryOfSignificantAccountingPoliciesTables 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://poci.com/role/SummaryOfSignificantAccountingPolicies 17 false false R18.htm 00000018 - Disclosure - 2. INVENTORIES (Tables) Sheet http://poci.com/role/InventoriesTables 2. INVENTORIES (Tables) Tables http://poci.com/role/Inventories 18 false false R19.htm 00000019 - Disclosure - 3. LEASE OBLIGATIONS (Tables) Sheet http://poci.com/role/LeaseObligationsTables 3. LEASE OBLIGATIONS (Tables) Tables http://poci.com/role/LeaseObligations 19 false false R20.htm 00000020 - Disclosure - 4. STOCK-BASED COMPENSATION (Tables) Sheet http://poci.com/role/Stock-basedCompensationTables 4. STOCK-BASED COMPENSATION (Tables) Tables http://poci.com/role/Stock-basedCompensation 20 false false R21.htm 00000021 - Disclosure - 5. REVENUE RECOGNITION (Tables) Sheet http://poci.com/role/RevenueRecognitionTables 5. REVENUE RECOGNITION (Tables) Tables http://poci.com/role/RevenueRecognition 21 false false R22.htm 00000022 - Disclosure - 6. BUSINESS ACQUISITION (Tables) Sheet http://poci.com/role/BusinessAcquisitionTables 6. BUSINESS ACQUISITION (Tables) Tables http://poci.com/role/BusinessAcquisition 22 false false R23.htm 00000023 - Disclosure - 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Loss per share) Sheet http://poci.com/role/SummaryOfSignificantAccountingPoliciesDetails-LossPerShare 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Loss per share) Details http://poci.com/role/SummaryOfSignificantAccountingPoliciesTables 23 false false R24.htm 00000024 - Disclosure - 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://poci.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://poci.com/role/SummaryOfSignificantAccountingPoliciesTables 24 false false R25.htm 00000025 - Disclosure - 2. INVENTORIES (Details) Sheet http://poci.com/role/InventoriesDetails 2. INVENTORIES (Details) Details http://poci.com/role/InventoriesTables 25 false false R26.htm 00000026 - Disclosure - 3. LEASE OBLIGATIONS (Details) Sheet http://poci.com/role/LeaseObligationsDetails 3. LEASE OBLIGATIONS (Details) Details http://poci.com/role/LeaseObligationsTables 26 false false R27.htm 00000027 - Disclosure - 3. LEASE OBLIGATIONS (Details Narrative) Sheet http://poci.com/role/LeaseObligationsDetailsNarrative 3. LEASE OBLIGATIONS (Details Narrative) Details http://poci.com/role/LeaseObligationsTables 27 false false R28.htm 00000028 - Disclosure - 4. STOCK-BASED COMPENSATION (Details - Stock based compensation) Sheet http://poci.com/role/Stock-basedCompensationDetails-StockBasedCompensation 4. STOCK-BASED COMPENSATION (Details - Stock based compensation) Details http://poci.com/role/Stock-basedCompensationTables 28 false false R29.htm 00000029 - Disclosure - 4. STOCK-BASED COMPENSATION (Details - Option activity) Sheet http://poci.com/role/Stock-basedCompensationDetails-OptionActivity 4. STOCK-BASED COMPENSATION (Details - Option activity) Details http://poci.com/role/Stock-basedCompensationTables 29 false false R30.htm 00000030 - Disclosure - 4. STOCK-BASED COMPENSATION (Details - Options by exercise price) Sheet http://poci.com/role/Stock-basedCompensationDetails-OptionsByExercisePrice 4. STOCK-BASED COMPENSATION (Details - Options by exercise price) Details http://poci.com/role/Stock-basedCompensationTables 30 false false R31.htm 00000031 - Disclosure - 4. STOCK-BASED COMPENSATION (Details Narrative) Sheet http://poci.com/role/Stock-basedCompensationDetailsNarrative 4. STOCK-BASED COMPENSATION (Details Narrative) Details http://poci.com/role/Stock-basedCompensationTables 31 false false R32.htm 00000032 - Disclosure - 5. REVENUE RECOGNITION (Details - Revenues) Sheet http://poci.com/role/RevenueRecognitionDetails-Revenues 5. REVENUE RECOGNITION (Details - Revenues) Details http://poci.com/role/RevenueRecognitionTables 32 false false R33.htm 00000033 - Disclosure - 5. REVENUE RECOGNITION (Details - Contract liabilities) Sheet http://poci.com/role/RevenueRecognitionDetails-ContractLiabilities 5. REVENUE RECOGNITION (Details - Contract liabilities) Details http://poci.com/role/RevenueRecognitionTables 33 false false R34.htm 00000034 - Disclosure - 6. BUSINESS ACQUISITION (Details) Sheet http://poci.com/role/BusinessAcquisitionDetails 6. BUSINESS ACQUISITION (Details) Details http://poci.com/role/BusinessAcquisitionTables 34 false false All Reports Book All Reports peye-20200331.xml peye-20200331.xsd peye-20200331_cal.xml peye-20200331_def.xml peye-20200331_lab.xml peye-20200331_pre.xml http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/srt/2020-01-31 http://fasb.org/us-gaap/2020-01-31 true true XML 27 R2.htm IDEA: XBRL DOCUMENT v3.20.1
CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
Mar. 31, 2020
Jun. 30, 2019
Current Assets:    
Cash and cash equivalents $ 632,131 $ 2,288,426
Accounts receivable (net of allowance for doubtful accounts of $247,701 and $246,953 at March 31, 2020 and June 30, 2019, respectively) 1,479,077 2,165,107
Inventories 2,167,523 1,734,604
Prepaid expenses 131,279 180,336
Total current assets 4,410,010 6,368,473
Fixed Assets:    
Machinery and equipment 2,905,516 2,748,715
Leasehold improvements 724,680 668,446
Furniture and fixtures 178,640 168,450
Total 3,808,836 3,585,611
Less: Accumulated depreciation and amortization 3,278,054 3,202,605
Net Fixed Assets 530,782 383,006
Operating lease right-to-use asset 132,000
Patents, net 86,908 54,087
Goodwill 687,664 687,664
TOTAL ASSETS 5,847,364 7,493,230
Current Liabilities:    
Current portion of capital lease obligation 70,436 9,572
Accounts payable 1,533,342 1,174,263
Customer advances 310,525 450,192
Accrued compensation and other 483,781 533,944
Amount due for business acquisition 0 1,443,341
Operating lease liability 56,196 0
Total Current Liabilities 2,454,280 3,611,312
Capital lease obligation, net of current portion 38,001 5,027
Acquisition earn out liability 500,000 500,000
Operating lease liability 75,804 0
Stockholders' Equity:    
Common stock, $0.01 par value: 50,000,000 shares authorized; issued and outstanding - 12,991,789 shares at March 31, 2020 and 12,071,139 shares at June 30, 2019 129,918 120,712
Additional paid-in capital 49,389,419 48,893,172
Accumulated deficit (46,740,058) (45,636,993)
Total stockholders' equity 2,779,279 3,376,891
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 5,847,364 $ 7,493,230
XML 28 R6.htm IDEA: XBRL DOCUMENT v3.20.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) - USD ($)
3 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Statement of Stockholders' Equity [Abstract]      
Exercise of stock options, net shares withheld 8,258 3,592  
Proceeds private placement stock, net of issuance costs     $ 23,000
XML 29 R28.htm IDEA: XBRL DOCUMENT v3.20.1
4. STOCK-BASED COMPENSATION (Details - Stock based compensation) - USD ($)
3 Months Ended 9 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Mar. 31, 2020
Mar. 31, 2019
Stock based compensation expense $ 75,567 $ 2,891 $ 426,778 $ 356,103
Cost of Goods Sold [Member]        
Stock based compensation expense 11,233 0 33,699 0
Research and Development Expenses [Member]        
Stock based compensation expense 21,346 2,411 46,714 7,233
Selling, General and Administrative Expenses [Member]        
Stock based compensation expense $ 42,988 $ 480 $ 346,365 $ 348,870
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.20.1
4. STOCK-BASED COMPENSATION (Tables)
9 Months Ended
Mar. 31, 2020
Share-based Payment Arrangement [Abstract]  
Schedule of stock-based compensation expense

The following table summarizes stock-based compensation expense for the three and nine months ended March 31, 2020 and 2019:

 

   Three Months
Ended March 31,
   Nine Months
Ended March 31,
 
   2020   2019   2020   2019 
Cost of Goods Sold  $11,233   $   $33,699   $ 
Research and Development   21,346    2,411    46,714    7,233 
Selling, General and Administrative   42,988    480    346,365    348,870 
Stock Based Compensation Expense  $75,567   $2,891   $426,778   $356,103 
Stock option activity

The following tables summarize stock option activity for the nine months ended March 31, 2020:

 

    Options Outstanding  
    Number of
Shares
    Weighted Average
Exercise Price
    Weighted Average
Contractual Life
 
Outstanding at June 30, 2019     1,819,500     $    0.87       7.05 years  
Granted     315,000                  
Exercised     (47,500 )                
Expired or Cancelled     (14,200 )                
Outstanding at March 31, 2020     2,072,800     $ 0.95       6.82 years  
Stock options outstanding by exercise price range

Information related to the stock options outstanding as of March 31, 2020 is as follows:

 

Range of Exercise
Prices
    Number of
Shares
    Weighted-
Average
Remaining
Contractual Life
(years)
    Weighted-
Average
Exercise
Price
    Exercisable
Number of
Shares
    Exercisable
Weighted-
Average
Exercise
Price
 
$ 0.27       40,000       1.29     $ 0.27       40,000     $ 0.27  
$ 0.48       60,000       6.00     $ 0.48       60,000     $ 0.48  
$ 0.50       100,000       5.22     $ 0.50       100,000     $ 0.50  
$ 0.55       44,000       3.96     $ 0.55       44,000     $ 0.55  
$ 0.70       100,000       8.35     $ 0.70       100,000     $ 0.70  
$ 0.73       786,000       6.56     $ 0.73       786,000     $ 0.73  
$ 0.85       6,000       2.76     $ 0.85       6,000     $ 0.85  
$ 0.90       36,000       4.19     $ 0.90       36,000     $ 0.90  
$ 1.20       207,800       1.92     $ 1.20       207,800     $ 1.20  
$ 1.25       45,000       1.25     $ 1.25       -     $ -  
$ 1.30       478,000       9.20     $ 1.30       -     $ -  
$ 1.42       100,000       9.45     $ 1.42       -     $ -  
$ 1.50       70,000       9.96     $ 1.50       70,000     $ 1.50  
$ 0.27–$1.50       2,072,800       6.82     $ 0.95       1,449,800     $ 0.79  
XML 31 R24.htm IDEA: XBRL DOCUMENT v3.20.1
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Mar. 31, 2020
Mar. 31, 2019
Accounting Policies [Abstract]        
Outstanding stock options and warrants that were excluded from the computation as their effect was antidilutive 2,072,800 1,462,000 2,072,800 1,462,000
Goodwill impairment $ 0 $ 0 $ 0 $ 0
XML 32 R10.htm IDEA: XBRL DOCUMENT v3.20.1
3. LEASE OBLIGATIONS
9 Months Ended
Mar. 31, 2020
Debt Disclosure [Abstract]  
LEASE OBLIGATIONS

3. LEASE OBLIGATIONS

 

The Company entered into a five-year capital lease obligation in January 2016 for the acquisition of manufacturing equipment totaling $51,252. In January 2020 the Company entered into a five-year capital lease and a twelve-month operating lease for $47,750 and $65,463 respectively for the acquisition of manufacturing equipment.

  

In February 2016, FASB issued ASU 2016-02, “Leases” (Topic 842). ASU 2016-02 requires the recognition of lease asset and lease liabilities by lessees for those leases currently classified as operating leases with terms greater than twelve months and make certain changes to the accounting for lease expenses. The Company adopted this standard effective July 1, 2019 and has reflected its impact upon the El Paso, Texas facility operating lease entered into on July 1, 2019 in connection with the Ross Optical acquisition. The facility lease is a three-year operating lease obligation with total remaining minimum lease payments of $139,791 at March 31, 2020. Total rent expense including base rent and common area expenses were $15,190 and $45,571 during the three and nine months ended March 31, 2020, respectively. Included in the accompanying balance sheet at March 31, 2020 is a right-of-use asset of $132,000 and current and long-term right-of-use operating lease liabilities of $56,196 and $75,804, respectively.

 

At March 31, 2020, future minimum lease payments under the capital lease and operating lease obligations are as follows:

 

Fiscal Year Ending June 30:   Capital Leases     Operating Lease  
2020   $ 21,748     $ 15,190  
2021     54,593       61,779  
2022     11,280       62,822  
2023     11,280        
2024     11,280        
2025     6,580        
Total Minimum Payments     116,761     $ 139,791  
Less: amount representing interest     8,324          
Present value of minimum lease payments     108,437          
Less: current portion     70,436          
    $ 38,001          
XML 33 R14.htm IDEA: XBRL DOCUMENT v3.20.1
7. COVID-19 PANDEMIC
9 Months Ended
Mar. 31, 2020
Covid-19 Pandemic  
COVID-19 PANDEMIC

7. COVID-19 PANDEMIC

 

The world-wide COVID-19 pandemic that began during the quarter ended March 31, 2020 and the domestic and international impact of policy decisions being made in major countries around the world has had, and is expected to have, an adverse impact on the Company’s sources of supply, current and future orders from the Company’s customers, collection of amounts owed to it from its customers, the Company’s internal operating procedures, and the Company’s overall financial condition. While the Company and many of its medical device and defense contracting customers continue to operate as essential businesses, the Company has taken various actions to augment its operating and human resource policies and procedures to guard against the potential health hazards of COVID-19. These augmented procedures can have a negative impact on the Company’s operational efficiencies. The Company sources various components from overseas suppliers throughout Asia, including China. The Company has experienced supply disruptions and customer delays, which it believes were the result of the COVID-19 pandemic and related economic slow-down. Given the uncertainty surrounding the continuation of economic slow-downs domestically and abroad, the Company cannot predict with certainty at this time what the future impact of COVID-19 and resulting business and economic policies in the US and abroad will be on its upcoming quarterly fiscal operating results.

XML 34 R18.htm IDEA: XBRL DOCUMENT v3.20.1
2. INVENTORIES (Tables)
9 Months Ended
Mar. 31, 2020
Inventory Disclosure [Abstract]  
Schedule of inventory

Inventories are stated at the lower of cost (first-in, first-out) and net realizable value and consisted of the following:

 

   March 31,
2020
   June 30,
2019
 
Raw Materials  $651,939   $578,856 
Work-In-Progress   743,100    409,019 
Finished Goods   772,484    746,729 
Total Inventories  $2,167,523   $1,734,604 
XML 36 R33.htm IDEA: XBRL DOCUMENT v3.20.1
5. REVENUE RECOGNITION (Details - Contract liabilities) - USD ($)
3 Months Ended 9 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Mar. 31, 2020
Mar. 31, 2019
Revenue from Contract with Customer [Abstract]        
Contract liabilities, beginning balance $ 388,506 $ 294,650 $ 450,192 $ 857,842
Unearned revenue received from customers 41,874 61,928 334,893 81,684
Revenue recognized in current period (119,855) (97,650) (474,560) (680,598)
Contract liabilities, ending balance $ 310,525 $ 258,928 $ 310,525 $ 258,928
XML 37 R4.htm IDEA: XBRL DOCUMENT v3.20.1
CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Mar. 31, 2020
Mar. 31, 2019
Income Statement [Abstract]        
Revenues $ 2,374,584 $ 1,386,454 $ 7,686,330 $ 4,423,763
Cost of goods sold 1,557,565 930,518 4,977,255 3,149,598
Gross profit 817,019 455,936 2,709,075 1,274,165
Research and development expenses, net 319,875 121,640 700,605 347,851
Selling, general and administrative expenses 962,591 414,475 3,111,397 1,430,880
Total operating expenses 1,282,466 536,115 3,812,002 1,778,731
Operating loss (465,447) (80,179) (1,102,927) (504,566)
Interest Income (expense) (683) (304) (138) (1,150)
Net loss $ (466,130) $ (80,483) $ (1,103,065) $ (505,716)
Loss Per Share:        
Basic and diluted $ (0.04) $ (0.01) $ (0.09) $ (0.04)
Weighted Average Common Shares Outstanding:        
Basic and diluted 12,982,494 12,020,328 12,898,004 11,294,902
XML 38 R22.htm IDEA: XBRL DOCUMENT v3.20.1
6. BUSINESS ACQUISITION (Tables)
9 Months Ended
Mar. 31, 2020
Business Combinations [Abstract]  
Pro forma operating results

Pro forma operating results include net adjustments resulting from the acquisition transaction.

 

   Three Months
Ended March 31,
   Nine Months
Ended March 31,
 
   2020   2019   2020   2019 
   (Actual)   (Pro Forma)   (Actual)   (Pro Forma) 
Revenues  $2,374,584   $2,413,438   $7,686,330   $7,348,803 
Net income (loss)   (466,130)   75,430    (1,103,065)   163,828 
Income (loss) per share                    
Basic  $(0.04)  $0.01   $(0.09)  $0.01 
Fully diluted  $(0.04)  $0.01   $(0.09)  $0.01 
XML 39 R26.htm IDEA: XBRL DOCUMENT v3.20.1
3. LEASE OBLIGATIONS (Details) - USD ($)
Mar. 31, 2020
Jan. 31, 2020
Jun. 30, 2019
Jan. 31, 2016
Capital lease future minimum payments        
2020 $ 21,748      
2021 54,593      
2022 11,280      
2023 11,280      
2024 11,280      
2025 6,580      
Total minimum payments 116,761      
Less: amount representing interest 8,324      
Present value of minimum lease payments 108,437 $ 65,463   $ 51,252
Less: current portion 70,436   $ 9,572  
Capital lease obligation, noncurrent 38,001   $ 5,027  
Operating lease future minimum payments        
2020 15,190      
2021 61,779      
2022 62,822      
2023 0      
2024 0      
2025 0      
Total minimum payments $ 139,791 $ 47,750    
XML 40 R8.htm IDEA: XBRL DOCUMENT v3.20.1
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
9 Months Ended
Mar. 31, 2020
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Principles of Consolidation and Operations

 

The accompanying consolidated financial statements include the accounts of Precision Optics Corporation, Inc. and its wholly owned subsidiaries (the “Company”). All significant intercompany accounts and transactions have been eliminated in consolidation.

 

These consolidated financial statements have been prepared by the Company, without audit, and reflect normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the results of the third quarter and nine months of the Company’s fiscal year 2020. These consolidated financial statements do not include all disclosures associated with annual consolidated financial statements and, accordingly, should be read in conjunction with footnotes contained in the Company’s consolidated financial statements for the year ended June 30, 2019, together with the Report of Independent Registered Public Accounting Firm filed under cover of the Company’s 2019 Annual Report on Form 10-K, filed with the Securities and Exchange Commission on September 26, 2019.

 

Use of Estimates

 

The preparation of these consolidated financial statements requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

 

Reclassification

 

Certain balance sheet items in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. This reclassification had no effect on the previously reported net loss.

 

Income (Loss) Per Share

 

Basic income (loss) per share is computed by dividing net income or net loss by the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share is computed by dividing net income or net loss by the weighted average number of shares of common stock outstanding during the period, plus the number of potentially dilutive securities outstanding during the period such as stock options and warrants. For the three and nine months ended March 31, 2020 and 2019, the effect of such securities was antidilutive and not included in the diluted calculation because of the net loss generated in these periods.

 

The following is the calculation of loss per share for the three and nine months ended March 31, 2020 and 2019:

 

   Three Months
Ended March 31,
   Nine Months
Ended March 31,
 
   2020   2019   2020   2019 
Net Loss - Basic and Diluted  $(466,130)  $(80,483)  $(1,103,065)  $(505,716)
                     
Basic and Dilutive Weighted Average Shares Outstanding   12,982,494    12,020,328    12,898,004    11,294,902 
                     
Loss Per Share - Basic and Diluted  $(0.04)  $(0.01)  $(0.09)  $(0.04)

 

The number of shares issuable upon the exercise of outstanding stock options and warrants that were excluded from the computation as their effect was antidilutive was approximately 2,072,800 and 1,462,000 for the three and nine months ended March 31, 2020 and 2019, respectively.

   

Income Taxes

 

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

 

In assessing the likelihood of utilization of existing deferred tax assets, management has considered historical results of operations and the current operating environment. Based on this evaluation, a full valuation reserve has been provided for the deferred tax assets.

 

Goodwill and Patents

 

Long-lived assets such as goodwill and patents are capitalized when acquired and reviewed for impairment whenever events or changes in circumstances indicate that the book value of the asset may not be recoverable. Impairment of the carrying value of long-lived assets such as goodwill and patents would be indicated if the best estimate of future undiscounted cash flows expected to be generated by the asset grouping is less than its carrying value. If an impairment is indicated, any loss is measured as the difference between estimated fair value and carrying value and is recognized in operating income or loss. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. No such impairments of goodwill or patents have been estimated by management as of March 31, 2020.

 

Accounting Pronouncements Recently Adopted

 

On July 1, 2019, the Company adopted ASU 2016-02, Topic 842 – Leases. Refer to Note 3 for further information.

XML 41 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 42 R23.htm IDEA: XBRL DOCUMENT v3.20.1
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Loss per share) - USD ($)
3 Months Ended 9 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Mar. 31, 2020
Mar. 31, 2019
Accounting Policies [Abstract]                
Net Loss - Basic and Diluted $ (466,130) $ (550,825) $ (86,110) $ (80,483) $ (125,948) $ (299,285) $ (1,103,065) $ (505,716)
Basic and Diluted Weighted Average Shares Outstanding 12,982,494     12,020,328     12,898,004 11,294,902
Loss Per Share - Basic and Diluted $ (0.04)     $ (0.01)     $ (0.09) $ (0.04)
XML 43 R9.htm IDEA: XBRL DOCUMENT v3.20.1
2. INVENTORIES
9 Months Ended
Mar. 31, 2020
Inventory Disclosure [Abstract]  
INVENTORIES

2. INVENTORIES

 

Inventories are stated at the lower of cost (first-in, first-out) and net realizable value and consisted of the following:

 

   March 31,
2020
   June 30,
2019
 
Raw Materials  $651,939   $578,856 
Work-In-Progress   743,100    409,019 
Finished Goods   772,484    746,729 
Total Inventories  $2,167,523   $1,734,604 
XML 44 R27.htm IDEA: XBRL DOCUMENT v3.20.1
3. LEASE OBLIGATIONS (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Mar. 31, 2020
Mar. 31, 2020
Jan. 31, 2020
Jun. 30, 2019
Jan. 31, 2016
Debt Disclosure [Abstract]          
Capital lease obligation $ 108,437 $ 108,437 $ 65,463   $ 51,252
Operating lease obligation 139,791 139,791 $ 47,750    
Operating lease expense 15,190 45,571      
Right of use operating lease 132,000 132,000    
Right of use operating lease current 56,196 56,196   0  
Right of use operating lease noncurrent $ 75,804 $ 75,804   $ 0  
XML 45 R1.htm IDEA: XBRL DOCUMENT v3.20.1
Document and Entity Information - shares
9 Months Ended
Mar. 31, 2020
May 14, 2020
Cover [Abstract]    
Entity Registrant Name PRECISION OPTICS CORPORATION, INC.  
Entity Central Index Key 0000867840  
Document Type 10-Q  
Document Period End Date Mar. 31, 2020  
Amendment Flag false  
Current Fiscal Year End Date --06-30  
Is Entity's Reporting Status Current? Yes  
Entity Filer Category Non-accelerated Filer  
Entity Common Stock, Shares Outstanding   13,191,789
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2020  
Entity Small Business true  
Entity Emerging Growth false  
Entity Interactive data current Yes  
Entity File number 001-10647  
Entity Incorporation state code MA  
Entity shell company false  
XML 46 R5.htm IDEA: XBRL DOCUMENT v3.20.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($)
Common Stock [Member]
Additional Paid-In Capital
Retained Earnings / Accumulated Deficit
Total
Beginning balance, shares at Jun. 30, 2018 10,197,139      
Beginning balance, value at Jun. 30, 2018 $ 101,972 $ 45,484,186 $ (45,022,122) $ 564,036
Issuance of common stock for services, shares 100,000      
Issuance of common stock for services, value $ 1,000 (1,000)    
Stock based compensation   342,984   342,984
Net loss     (299,285) (299,285)
Ending balance, shares at Sep. 30, 2018 10,297,139      
Ending balance, value at Sep. 30, 2018 $ 102,972 45,826,170 (45,321,407) 607,735
Beginning balance, shares at Jun. 30, 2018 10,197,139      
Beginning balance, value at Jun. 30, 2018 $ 101,972 45,484,186 (45,022,122) 564,036
Net loss       (505,716)
Ending balance, shares at Mar. 31, 2019 12,038,139      
Ending balance, value at Mar. 31, 2019 $ 120,382 47,839,004 (45,527,838) 2,431,548
Beginning balance, shares at Sep. 30, 2018 10,297,139      
Beginning balance, value at Sep. 30, 2018 $ 102,972 45,826,170 (45,321,407) 607,735
Issuance of stock, private placement, shares 1,600,000      
Issuance of stock, private placement, value $ 16,000 1,961,000   1,977,000
Stock based compensation   10,228   10,228
Net loss     (125,948) (125,948)
Ending balance, shares at Dec. 31, 2018 11,897,139      
Ending balance, value at Dec. 31, 2018 $ 118,972 47,797,398 (45,447,355) 2,469,015
Exercise of stock options, shares 41,000      
Exercise of stock options, value $ 410 28,965 29,375
Issuance of common stock for services, shares 100,000      
Issuance of common stock for services, value $ 1,000 (1,000)
Adjust common stock issuance costs to actual 10,750 10,750
Stock based compensation 2,891 2,891
Net loss (80,483) (80,483)
Ending balance, shares at Mar. 31, 2019 12,038,139      
Ending balance, value at Mar. 31, 2019 $ 120,382 47,839,004 (45,527,838) 2,431,548
Beginning balance, shares at Jun. 30, 2019 12,071,139      
Beginning balance, value at Jun. 30, 2019 $ 120,712 48,893,172 (45,636,993) 3,376,891
Issuance of stock, private placement, shares 760,000      
Issuance of stock, private placement, value $ 7,600 17,400   25,000
Exercise of stock options, shares 12,500      
Exercise of stock options, value $ 125 8,550   8,675
Issuance of common stock for services, shares 25,000      
Issuance of common stock for services, value $ 250 44,750   45,000
Stock based compensation   76,505   76,505
Net loss     (86,110) (86,110)
Ending balance, shares at Sep. 30, 2019 12,868,639      
Ending balance, value at Sep. 30, 2019 $ 128,687 49,040,377 (45,723,103) 3,445,961
Beginning balance, shares at Jun. 30, 2019 12,071,139      
Beginning balance, value at Jun. 30, 2019 $ 120,712 48,893,172 (45,636,993) 3,376,891
Net loss       (1,103,065)
Ending balance, shares at Mar. 31, 2020 12,991,789      
Ending balance, value at Mar. 31, 2020 $ 129,918 49,389,419 (46,740,058) 2,779,279
Beginning balance, shares at Sep. 30, 2019 12,868,639      
Beginning balance, value at Sep. 30, 2019 $ 128,687 49,040,377 (45,723,103) 3,445,961
Exercise of stock options, shares 11,408      
Exercise of stock options, value $ 114 (114)    
Stock based compensation   274,706   274,706
Net loss     (550,825) (550,825)
Ending balance, shares at Dec. 31, 2019 12,880,047      
Ending balance, value at Dec. 31, 2019 $ 128,801 49,314,969 (46,273,928) 3,169,842
Exercise of stock options, shares 11,742      
Exercise of stock options, value $ 117 (117)
Issuance of common stock for services, shares 100,000      
Issuance of common stock for services, value $ 1,000 (1,000)
Stock based compensation 75,567 75,567
Net loss (466,130) (466,130)
Ending balance, shares at Mar. 31, 2020 12,991,789      
Ending balance, value at Mar. 31, 2020 $ 129,918 $ 49,389,419 $ (46,740,058) $ 2,779,279
XML 47 R19.htm IDEA: XBRL DOCUMENT v3.20.1
3. LEASE OBLIGATIONS (Tables)
9 Months Ended
Mar. 31, 2020
Debt Disclosure [Abstract]  
Future minimum lease payments

3. LEASE OBLIGATIONS

 

The Company entered into a five-year capital lease obligation in January 2016 for the acquisition of manufacturing equipment totaling $51,252. In January 2020 the Company entered into a five-year capital lease and a twelve-month operating lease for $47,750 and $65,463 respectively for the acquisition of manufacturing equipment.

  

In February 2016, FASB issued ASU 2016-02, “Leases” (Topic 842). ASU 2016-02 requires the recognition of lease asset and lease liabilities by lessees for those leases currently classified as operating leases with terms greater than twelve months and make certain changes to the accounting for lease expenses. The Company adopted this standard effective July 1, 2019 and has reflected its impact upon the El Paso, Texas facility operating lease entered into on July 1, 2019 in connection with the Ross Optical acquisition. The facility lease is a three-year operating lease obligation with total remaining minimum lease payments of $139,791 at March 31, 2020. Total rent expense including base rent and common area expenses were $15,190 and $45,571 during the three and nine months ended March 31, 2020, respectively. Included in the accompanying balance sheet at March 31, 2020 is a right-of-use asset of $132,000 and current and long-term right-of-use operating lease liabilities of $56,196 and $75,804, respectively.

 

At March 31, 2020, future minimum lease payments under the capital lease and operating lease obligations are as follows:

 

Fiscal Year Ending June 30:   Capital Leases     Operating Lease  
2020   $ 21,748     $ 15,190  
2021     54,593       61,779  
2022     11,280       62,822  
2023     11,280        
2024     11,280        
2025     6,580        
Total Minimum Payments     116,761     $ 139,791  
Less: amount representing interest     8,324          
Present value of minimum lease payments     108,437          
Less: current portion     70,436          
    $ 38,001          
XML 48 R11.htm IDEA: XBRL DOCUMENT v3.20.1
4. STOCK-BASED COMPENSATION
9 Months Ended
Mar. 31, 2020
Share-based Payment Arrangement [Abstract]  
STOCK-BASED COMPENSATION

4. STOCK-BASED COMPENSATION

 

The following table summarizes stock-based compensation expense for the three and nine months ended March 31, 2020 and 2019:

 

   Three Months
Ended March 31,
   Nine Months
Ended March 31,
 
   2020   2019   2020   2019 
Cost of Goods Sold  $11,233   $   $33,699   $ 
Research and Development   21,346    2,411    46,714    7,233 
Selling, General and Administrative   42,988    480    346,365    348,870 
Stock Based Compensation Expense  $75,567   $2,891   $426,778   $356,103 

  

No compensation has been capitalized because such amounts would have been immaterial.

   

The following tables summarize stock option activity for the nine months ended March 31, 2020:

 

    Options Outstanding  
    Number of
Shares
    Weighted Average
Exercise Price
    Weighted Average
Contractual Life
 
Outstanding at June 30, 2019     1,819,500     $    0.87       7.05 years  
Granted     315,000                  
Exercised     (47,500 )                
Expired or Cancelled     (14,200 )                
Outstanding at March 31, 2020     2,072,800     $ 0.95       6.82 years  

 

Information related to the stock options outstanding as of March 31, 2020 is as follows:

 

Range of Exercise
Prices
    Number of
Shares
    Weighted-
Average
Remaining
Contractual Life
(years)
    Weighted-
Average
Exercise
Price
    Exercisable
Number of
Shares
    Exercisable
Weighted-
Average
Exercise
Price
 
$ 0.27       40,000       1.29     $ 0.27       40,000     $ 0.27  
$ 0.48       60,000       6.00     $ 0.48       60,000     $ 0.48  
$ 0.50       100,000       5.22     $ 0.50       100,000     $ 0.50  
$ 0.55       44,000       3.96     $ 0.55       44,000     $ 0.55  
$ 0.70       100,000       8.35     $ 0.70       100,000     $ 0.70  
$ 0.73       786,000       6.56     $ 0.73       786,000     $ 0.73  
$ 0.85       6,000       2.76     $ 0.85       6,000     $ 0.85  
$ 0.90       36,000       4.19     $ 0.90       36,000     $ 0.90  
$ 1.20       207,800       1.92     $ 1.20       207,800     $ 1.20  
$ 1.25       45,000       1.25     $ 1.25       -     $ -  
$ 1.30       478,000       9.20     $ 1.30       -     $ -  
$ 1.42       100,000       9.45     $ 1.42       -     $ -  
$ 1.50       70,000       9.96     $ 1.50       70,000     $ 1.50  
$ 0.27–$1.50       2,072,800       6.82     $ 0.95       1,449,800     $ 0.79  

 

The aggregate intrinsic value of the Company’s “in-the-money” outstanding and exercisable options as of the three and nine months ended March 31, 2020 was $941,830 and $887,280, respectively.

 

Common Stock Award

 

On August 2, 2018, the Company awarded its Chief Executive Officer 300,000 shares of common stock for services performed through June 30, 2018. The fair market value of the 300,000 shares on the award date equal to $210,000 has been recorded as general and administrative stock-based compensation expense in the quarter ended September 30, 2018. As of March 31, 2020, all 300,000 shares have been issued.

XML 49 R15.htm IDEA: XBRL DOCUMENT v3.20.1
8. SUBSEQENT EVENT
9 Months Ended
Mar. 31, 2020
Subsequent Events [Abstract]  
SUBSEQUENT EVENT

8. SUBSEQUENT EVENT

 

On April 14, 2020, the Company entered into agreements with accredited investors for the sale and purchase of 200,000 shares of its common stock, $0.01 par value at a purchase price of $1.25 per share. The Company received $250,000 in gross proceeds from the offering. The Company entered into this stock offering transaction in order to enhance its financial condition given uncertainties surrounding the COVID-19 pandemic and its potential impact on domestic and international sources of supply as well as the financial condition of its customers and the status of existing and future sales orders from them. The agreements also provide for the investors to receive additional shares of our common stock in the event the Company closes a subsequent offering of its common stock at a purchase price lower than $1.25 per share before April 14, 2021. The additional shares each investor would receive would be equal to the difference between the number of shares that would have been received at the reduced purchase price and the number of shares received at the $1.25 purchase price. The Company intends to use the proceeds from this placement for general working capital purposes.

 

In conjunction with the placement, the Company also entered into a registration rights agreement with the investors, whereby it is obligated to file a registration statement with the Securities Exchange Commission on or before 120 calendar days after April 14, 2020 to register the resale by the investors of 200,000 shares of our common stock purchased in the placement.

 

On May 6, 2020, the Company received loan proceeds in the amount of $808,962 under the Paycheck Protection Program, or PPP, from Bank of America. The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act, or CARES Act, provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The loans and accrued interest are forgivable after eight weeks as long as the Company uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and we maintain our payroll levels. The amount of loan forgiveness will be reduced if the Company terminates employees or reduces salaries during the eight-week period.

 

The unsecured loan, which is in the form of a note dated May 6, 2020, matures on May 6, 2022 and bears interest at a rate of 1% per annum, payable monthly commencing on December 6, 2020. The note may be prepaid at any time prior to maturity with no prepayment penalties. The Company intends to use the loan amount for eligible purposes, such as payroll expenses. While the Company currently believes that its use of the loan proceeds will meet the conditions for forgiveness of the loan, the Company cannot assure that it will be eligible for forgiveness, in whole or in part.

XML 50 R32.htm IDEA: XBRL DOCUMENT v3.20.1
5. REVENUE RECOGNITION (Details - Revenues) - USD ($)
3 Months Ended 9 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Mar. 31, 2020
Mar. 31, 2019
Revenues $ 2,374,584 $ 1,386,454 $ 7,686,330 $ 4,423,763
Engineering Design Services [Member]        
Revenues 210,065 61,833 1,098,234 892,472
Optical Components [Member]        
Revenues 1,479,322 250,405 4,428,409 774,429
Medical Device Products and Assemblies [Member]        
Revenues $ 685,197 $ 1,074,216 $ 2,159,687 $ 2,756,862